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Characterization of biopharmaceuticals is necessary for ensuring their purity and structural 
integrity. Many classes of biopharmaceutical drugs are turbid solutions. Common optical 
characterization techniques such as absorbance and FTIR spectroscopy must be adapted for use 
with turbid solutions. The goal of this thesis is to develop and apply spectroscopic techniques for 
characterizing turbid solutions. In the first chapter we introduce the current techniques employed 
for characterization of biopharmaceuticals. Special attention is paid to spectroscopic techniques 
and possible pitfalls of their use with turbid solutions. In the second chapter we develop a new 
method for measuring absorbance spectra of turbid solutions. The chapters three through five we 
apply a variety of spectroscopic techniques to characterize three distinct turbid solutions: 
aggregated proteins, phase separated antibodies, and mRNA-cationic lipid nanoparticles. 
Chapter two describes a label-free, direct approach to measure protein concentrations in 
turbid solutions using a UV-Vis integrating cavity absorbance spectrometer. Protein-particle 
conjugates and mixtures have been investigated extensively for their diverse applications in 
biotechnology. However, general methods to measure protein concentration of protein-particle 
solutions are lacking. Typically, proteins in turbid solutions require separation or staining with 
another chromophore to quantitate their concentration. Three systems are used to test the ability 
to measure accurate protein concentrations: proteins adsorbed to Alhydrogel, proteins in solution 
with gold nanoparticles and proteins encapsulated within polymeric microspheres. Protein 
concentrations in each of the three protein-particle systems were successfully quantified using a 
calibration curve created from the absorbance at 280 nm.   
In chapter three we study the two main pathways of Polysorbate 80 (PS80) degradation, 
enzymatic ester hydrolysis and oxidation. Polysorbates are used ubiquitously in protein 
therapeutic drugs to help minimize adsorption to surfaces and aggregation. It has been 
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recognized that polysorbate can itself degrade and in turn result in loss of efficacy of therapeutic 
proteins. Degraded polysorbates were quantified through mass spectrometry to identify the loss 
of individual components. Next Langmuir trough adsorption isotherms were used to characterize 
changes in the surface activity of the degraded polysorbates. PS80 degraded via hydrolysis results 
in slower surface adsorption rates, while the oxidized PS80 show increased surface activity. 
However, the critical micelle concentration remained unchanged. A monoclonal antibody was 
formulated with stock and degraded polysorbates to probe their ability to prevent aggregation. 
Hydrolyzed polysorbate resulted in a large increase in particle formation during shaking stress. 
Oxidized PS80 was still protective against aggregation for the monoclonal antibody. Monomer 
loss as measured by SEC was comparable in formulations without PS80 to those with esterase 
hydrolyzed PS80. Monomer loss for oxidized PS80 was similar to that of non-degraded PS80. 
Hydrolysis of PS80 resulted in free fatty acids which formed insoluble particles during 
mechanical agitation which stimulated protein aggregation. 
In chapter four we characterize three immunoglobulins which undergo liquid-liquid phase 
separation with the goal of better understanding how intermolecular protein-protein interactions 
affect protein conformation in the protein-rich phase. We performed extensive and direct 
physical characterization of both the protein-rich and protein-poor phases. In comparison, the 
protein-rich phases displayed blue-shifted tryptophan emission spectra and their amide I infrared 
absorbance spectra red shifted for all three immunoglobulins. We used Raman spectroscopy to 
observe disulfide bonds which were isomerized to higher energy strained conformations in the 
protein-rich phases. Changes in the structural organization of water molecules within the 
protein-rich phase for all three antibodies were observed, suggesting a role for water hydrogen-
bonding in phase separation. Amide I and protein fluorescence spectra differences between the 
phases persisted at temperatures above the critical temperature, but ceased at the temperature 
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where these proteins unfolded. Hydrogen exchange-mass spectrometry (HX-MS) analysis with 
two of the mAbs identified specific regions driving protein reversible self-association. For one of 
the antibodies, electrostatic interactions between two oppositely charged patches on the Fab 
region appeared to initiate protein self-interactions. For another antibody, a large hydrophobic 
patch on the IgG1 heavy chain variable domain facilitated protein self-interaction. We 
hypothesized that aggregation would occur at equivalent rates in both phases since the two 
phases have the same chemical potential. For two of the antibodies, the protein-poor phase 
aggregated more rapidly than the protein-rich phase, while the third antibody displayed equal 
rates in the two phases. 
In chapter five we characterize the effect of solution pH on mRNA–cationic lipid 
nanoparticles (mRNA–LNPs) structure and transfection efficiency. LNPs containing mRNA are 
able to deliver genetic material to cells for use as vaccines or protein replacement therapies. We 
compared the structural and colloidal properties of LNPs not containing mRNA and mRNA free 
in solution with mRNA–LNPs. We used a combination of biophysical techniques to build a 
picture of the structure of the lipids and mRNA across pH and temperature in the form of an 
empirical phase diagram (EPD). A combination of FTIR spectroscopy and differential scanning 
calorimetry was used to investigate lipid phase behavior. The mRNA–LNPs transition from an 
inverse hexagonal phase at pH values below the pKa of the cationic lipid to a lamellar phase 
above the pKa. At higher temperatures the mRNA–LNPs also transition from an inverse 
hexagonal phase to a lamellar phase indicating the inverse hexagonal phase is more 
thermodynamically favorable.  Circular dichroism was used to investigate changes to the mRNA. 
The mRNA within the LNP has more A form structure at pH’s below the pKa than above it. 
Optical density, zeta potential and dynamic light scattering measurements were used to probe 
the colloidal stability of the mRNA–LNPs. The particles were larger and more prone to 
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aggregation below the pKa. A stability study was performed to relate the biophysical 
characteristics to the storage of the particles in solution at 4 and 25 °C. mRNA–LNPs had the 
highest transfection efficiency and stability at pH values below the pKa. However, there was a 
trade-off between the stability and aggregation propensity since at very low pH the particles were 
most prone to aggregation. We performed kinetic experiments to show that the time scale of the 
pH-dependent phase behavior is slow (6 hr transition) and the transition from lamellar to inverse 
hexagonal is irreversible. This suggests that the lamellar phase is less-stable and kinetically 
trapped. Our findings deepen our structural understanding of mRNA–LNPs and will aid in the 
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1.1 Thesis overview  
Characterization of drug products is critical to determine purity and structural integrity. 
Many classes of biopharmaceuticals are turbid. Some examples are: aluminum-adjuvanted 
vaccines, proteins at high concentration, and nano- and micro-particle-based drugs. Optical 
techniques for characterizing biopharmaceuticals have limitations due to the loss of scattered 
light from turbid solutions. In some cases, these limitations can be worked around by altering the 
geometry of the optical measurement. For instance, fluorescence spectroscopy of turbid solutions 
can be performed in a backscattering geometry so that scattered fluorescence light can reach the 
detector. The purpose of this thesis is to develop new techniques for turbid solution 
characterization and to apply a of variety of techniques to better characterize specific turbid 
biopharmaceutical solutions.  
In chapter one we outline techniques to characterize biopharmaceutical solutions of 
proteins. Techniques to characterize each level of protein structure are described. We focus on 
techniques which can be applied with relatively high throughput for use in formulation 
development. Special attention is paid to spectroscopic techniques and their limitations for use 
with turbid solutions. 
In chapter two we develop a novel method for absorbance spectroscopy measurements in 
turbid solutions. This method uses an integrating cavity absorbance spectrometer which is a 
spherical cuvette coated in a reflective material so that most or all of the scattered light reaches 
the detector. We show for a variety of turbid protein solutions that concentrations can be 
accurately quantified using integrating-cavity absorbance spectroscopy. 
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In chapter three we determine the effects of polysorbate 80 (PS80) degradation on the 
stability of a monoclonal antibody. Aggregation of proteins in solution results in particles and 
solution turbidity. PS80 is a nonionic surfactant which is commonly added to biopharmaceutical 
formulations to prevent aggregation. However, PS80 itself can degrade and in some cases has 
been shown to accelerate protein aggregation. We compare the effects of the two most common 
degradation pathways for PS80 – hydrolysis and oxidation – on protein aggregation.  
In chapter four we characterize the biophysical properties of phase separated solutions of 
monoclonal antibodies. Previous work on phase separated solutions had been performed 
following dilution of the phases to circumvent having to measure the turbid protein-rich phase. 
Here, we use techniques capable of measuring turbid solutions directly and identify a number of 
differences between the protein-rich and -poor phases in terms of the secondary and tertiary 
structure of the constituent proteins. We apply hydrogen-deuterium exchange mass spectrometry 
to determine specific sequences involved in protein self-association. The differences in 
aggregation propensity of the antibodies is also examined. 
In chapter five we focus on the pH-dependence of the physical properties of mRNA–
cationic lipid nanoparticles. mRNA–lipid nanoparticles deliver coding nucleic acids for use as 
vaccines or protein-replacement therapies. mRNA–lipid nanoparticles are approximately one 
hundred nanometers in diameter. The intensity of scattered light has a power dependence on 
particle size (on the order of the power of six for Rayleigh scattering) and therefore solutions of 
mRNA–lipid nanoparticles are turbid. We use techniques capable of characterizing both the 
lipid phase behavior and mRNA structure within the lipid nanoparticles to determine the pH-
dependence around the pKa of the cationic lipid. An accelerated short-term stability study of the 
mRNA–lipid nanoparticles is also performed at five pH and two temperatures. 
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1.2 Biophysical Characterization and the Development of Therapeutic 
Proteins 
A critical element in the development of drugs involves their structural analysis at both the 
chemical and physical level. With small molecules, this can be accomplished with high precision 
and resolution with techniques such as crystallography, NMR, and mass spectrometry among 
other methods. The large size and complexity of macromolecular drugs (e.g., proteins, nucleic 
acids, vaccines, etc.) usually require a somewhat different approach involving multiple lower 
resolution methods that can be combined into a multiple faceted picture of the macromolecule. 
While crystallography, cryo-electron microscopy, and NMR can provide high-resolution 
structures of proteins, nucleic acids, and some macromolecule complexes, they are usually not 
applicable to pharmaceutical development due to size, physical state, and other limitations. We 
will here limit our discussion to methods that are usually available to the non-expert due to their 
simplicity of operation and availability. Furthermore, we will only consider proteins with an 
emphasis on monoclonal immunoglobulins with a few examples to better illustrate certain 
techniques, although much of what we will discuss is more widely applicable. More detailed 
information can be obtained in the references and in some cases in the figure legends.  
When discussing the structure of proteins, it is usual to classify levels of organization into 
four categories. These are the primary (the amino acid sequence), secondary (reflecting local 
interactions such as helices, sheets, and turns), tertiary (aspects of the overall three-dimensional 
structure), and quaternary (subunit and aggregative nature) structures. Different methods can be 
used to examine and sometimes quantitate various aspects of this classification system. We will 
employ this convention in our discussion here.  
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1.2.1 Primary Structure  
In the past, the sequencing of proteins was performed using the Edman degradation 
reaction in an automated instrument. Currently, we almost always use some form of peptide 
mapping. In this method, a protein is digested with one or more proteases. The digest is 
separated into individual peptides by chromatography (usually reversed-phase HPLC) and their 
molecular weights determined by high-resolution mass spectrometry. Subtle changes like those 
produced by deamidation and oxidation can be analyzed by an initial chromatography step to 
separate modified forms followed by peptide mapping. The high resolution of modern mass 
spectrometers (less than 10 ppm) allows single dalton changes as seen in deamidation events to be 
detected. Such methods have become sufficiently routine that they can be used in stability studies 
(Figure 1.1)1.  
It is common that lesser resolution methods are often used across all stages of development. 
The best known of these is SDS polyacrylamide electrophoresis (SDS-PAGE). In this method, 
proteins are unfolded by sodium dodecyl sulfate (SDS) into rodlike extended structures whose 
length is proportional to their molecular weight. The proteins are then separated by electric field-
induced passage through a polyacrylamide matrix where they migrate approximately 
proportional to the log of their molecular weight. The proteins are stained by a dye, and their 
relative mobilities are obtained. This method is not usually sufficient to detect single amino acid 
changes but can often resolve small changes in molecular weight and larger changes such as 
oligomerization if these associations are not disrupted by the SDS. A reducing agent is usually 
included to aid in the unfolding of the proteins and to separate disulfide-linked subunits. Despite 
its lack of sensitivity, this method is widely used due to its speed and convenience.  
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Figure 1.1. Recombinant antigen A is a 42 kDa multi-epitope antigen produced during the 
development of a broadly effective vaccine for group A Streptococcus. Shown are peptide maps of 
antigen A produced by Lys C digestion at pH 6.0, 7.0, and 8.0. Proteolysis was performed for 7 days at 4 
°C and then resolved and analyzed by LC/MS as described. (See reference1)  
Isoelectric focusing is also used to characterize primary structure because it is sensitive to 
charge differences. Although once a cumbersome technique when performed in urea gels, it is 
now typically performed in ampholyte (a mixture of charged peptides) containing capillaries with 
laser detection. Single-site changes involving charge residues are easily seen. For example, the 
spectrotypes of immunoglobulins resulting from individual deamidation events and sialyation 
differences are well resolved2. Similarly, reversed-phase or ion-exchange HPLC is often 
sufficiently sensitive to detect small changes in sequence.  
1.2.2 Secondary Structure  
Circular dichroism (CD) is a method based on differences in optical absorption of left- and 
right-handed circularly polarized light3. It is particularly useful for characterization of both 
protein secondary and tertiary (see below) structure. During an absorption event, there is a 
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change in the distribution of charge that can be described by a transition dipole moment. In the 
case of an asymmetric molecule, there is also an absorption-induced magnetic dipole moment, 
which is circular in nature. The interaction of these two components is through their dot product, 
which results in a helical circularization of charge. Thus, molecules which contain circularly 
averaged absorptive entities such as the peptide bonds in α-helices and to a lesser extent β-
structure and various turns possess strong to weak circular dichroism.  
In proteins, the interaction between the peptide bonds causes splitting of the CD signal that 
results in characteristic spectra (measured as the difference in the absorption of the two forms of 
circularly polarized light as a function of wavelength) for different secondary structure types in 
the 180–250 nm region. Spectra are normalized for mean residue molar concentration and can 
be deconvoluted to produce relative contents of the different secondary structure types based on 
reference spectra. This is automated in the software of modern spectropolarimeters. Changes in 
temperature, pH, and other variables of interest often produce alterations that involve 
perturbation of secondary structure as a function of various forms of stress to be quantitatively 
analyzed. Plots of spectral changes (typically molar ellipticity for normalization purposes to 
permit comparison of spectra between different proteins) can be used to detect conformational 
changes in terms of secondary structure alterations (Figure 1.2a, b)4. Contributions of other 
chromophores such as aromatic side chains and disulfide bonds in the 290 – 220 nm region can 
sometimes complicate interpretation.  
There are a wide range of conditions under which CD spectra in the far UV can be 
obtained but also distinct limitations. A common protein concentration used is 0.1 – 0.2 mg/mL 
with a 0.1 cm pathlength (PL) cell. Much higher concentrations can be examined with short 
PLs5. For example, spectra of proteins at concentrations of 180 mg/mL can be obtained with 3 
μm cuvettes6. Conversely, low concentrations can be examined with long PL cells. The only 
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problem here is that when concentrations below 10 μg/mL are tested, a significant portion of the 
sample may be adsorbed to the inner surface of the cuvette which could alter their structure.  
A common problem in obtaining CD spectra is absorption in the UV region by solutes. 
Most buffers and other solutes absorb in the far UV region. Thus, keeping the concentration of 
such agents low is highly desirable but may be limited by their stabilizing effects and actual 
interest in their effects on target proteins. Another problem is the phenomenon known as 
absorption flattening. When the size of investigated agents becomes larger, they begin to shadow 
one another, i.e., particles no longer see actual incident light. The effect is to reduce the intensity 
of the CD signal (it typically becomes less negative), and it shifts to the red. This is commonly 
seen when proteins aggregate. Thus, one should confirm a lack of aggregation by concentration 
independence of the observed CD signal. A less frequently encountered artifact is differential 
scattering of left and right circularly polarized light, but this is rarely seen. We should also 
mention that modern spectropolarimeters may also permit near UV CD, absorbance, scattering, 
and even fluorescence to be simultaneously monitored (see later). They may also possess multiple 
sampling capability and even be found in microtiter plate formats. Therefore, CD can in some 
cases be used for high-throughput screening.  
A second method that is widely used for protein secondary structure analysis is Fourier 
transform infrared (FTIR) spectroscopy7. This technique is based primarily on changes in 
vibrations of the peptide bond. Originally, the use of dispersive instruments permitted only very 
high concentrations to be studied which produced low-resolution spectra. Furthermore, 
interference by water signals was a problem that had to be reduced by the unsatisfactory solution 
of the use of D2O as the solvent. This has changed dramatically in the last 30 years with the 
advent of Fourier transform instruments and sampling methods such as an attenuated total 
reflectance (ATR) which has allowed high-resolution spectra to be measured at much lower 
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concentration (e.g., 0.1 mg/mL). Due to the coupling of FTIR data to mathematical methods to 
deconvolute spectral bands, FTIR spectroscopy now rival or even exceed CD in its utility for 
protein secondary structure analysis.  
Most studies focus on the amide I band from 1600 to 1700 cm–1. This broad highly 
structured but poorly resolved peak arises primarily from CO stretching and to a lesser extent 
from CN stretching and CCN deformation. There are many additional amide bands (amide A 
and B and II–VII), but these are less frequently employed. The usual elements of secondary 
structure (e.g., α-helix, β-structure, turns, loops, and disordered regions) all produce at least one 
and sometimes more distinct peaks that can usually be resolved by some combination of Fourier 
self- deconvolution, derivative analysis, and curve fitting7. Less common structured forms such as 
the 310-helix, poly (L-Pro) helix, and the left-handed α-helix can also be detected. A very strong 
signal is produced in the 1610 – 1620 cm–1 region by aggregated protein due to the cross-beta 
nature of the interactions between high associated materials. This signal may be of special 
importance to the pharmaceutical scientist due to the need to detect aggregated protein as a 
degradant in protein samples (Figure 1.3)8.  
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Figure 1.2. Biophysical characterization of an IgG1 mAb as a function of temperature and pH. (a) 
CD spectra at 10 °C, (b) CD intensity change at 217 nm with temperature, (c) ANS spectra at 10 °C, (d) 
ANS melting curve at 486 nm, (e) fluorescence intensity versus temperature, (f) fluorescence peak 
position changes with temperatures, (g) static light-scattering intensity change with temperature, and (h) 
empirical phase diagram (EPD) analysis of this data. Data shown for n = 3 measurements. (See 
reference4)  
Although transmittance was initially used as the most common sampling geometry, its 
application has been reduced by the use of attenuated total reflectance geometries. The very high 
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precision of such methods allow water signals to be quantitatively subtracted and subsequently 
quantitative secondary structural analysis to be performed. A number of amino acid side chains 
also absorb in the amide I region (Asn, Glu, Arg, Lys, His, Tyr, etc. with their contribution 
depending on their state of ionization). These signals are usually weak and therefore ignored, but 
an unusually high concentration of a particular side chain may require its subtraction before 
secondary structure analysis is performed. Values of the extinction coefficients of side chains are 
available for this purpose9, 10.  
Unlike CD, FTIR spectroscopy has been routinely used to examine proteins in the solid 
state. This is usually done either by grinding the protein solid with IR transparent KBr and 
compressing a pellet or by the use of diffuse reflectance or ATR. This has been especially useful 
to search for protein structural changes in lyophilized formulations. As with CD, interference by 
solutes needs to be considered. Any substances with bonds will produce IR spectra although 
spectral windows in amide regions can sometimes be found. One can unfold proteins by a salt 
such as LiBr, but many common chaotropic agents such as urea and guanidine HCl are usually 
of little use due to their strong IR absorbance. The usual solution variables of interest 
(temperature, pH, ionic strength) can all be easily studied by FTIR spectroscopy. FTIR 
instruments are often significantly cheaper than spectropolarimeters further increasing the 
attractiveness of this technique.  
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Figure 1.3. Fourier transform infrared analysis of an IgG2 mAb as a function of pH and 
temperature. Representative FTIR absorbance and second-derivative spectra of the IgG2 mAb at 
indicated solution pH before and after heat treatment (a). FTIR differential absorbance of the IgG2 mAb 
as (a function of pH and temperature as monitored at 1637 (b), 1620 (c), and 1668 cm−1 (d). FTIR spectra 
were baseline corrected and vector normalized between 1590 and 1710 cm–1. The peak at 1620 cm–1 
reflects aggregation of the protein. Differential absorbance data at 1668 cm–1 was parallelly shifted by one 
or multiples of 0.002 units for clearer presentation of the data. Error bars represent 1 SD with n = 2. (See 
reference8) 
A second vibration-based technique that can be used to examine the secondary structure of 
proteins is Raman spectroscopy11. The difference in spectra between the infrared and Raman 
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methods lies in their unique spectral selection rules. An infrared active transition requires a 
change in dipole moment, while Raman involves an alteration in polarizability. Vibrational 
transitions can be IR active, Raman active, or both. The utility of the Raman method was 
dramatically enhanced by the advent of lasers, which enhanced naturally weak Raman signals. 
Raman spectroscopy is actually a light-scattering method in which scattered light shifts both up 
and down in frequency due to interactions with the vibrational transitions of target molecule. 
The difference in frequency of the incident (laser) light with vibrational transitions constitutes the 
Raman spectrum. The weak signals produced even with laser excitation require relatively high 
protein concentration (5–10 mg/mL). Amide bands are present, but the amide III band is often 
preferred due to its structure and separation of the individual secondary structure element 
signals. Unlike FTIR spectroscopy, amino acid side chain signals are often easily resolved making 
the technique of potentially broader utility. Like FTIR spectroscopy, the Raman method can be 
applied in both the liquid (aqueous) and solid state. Water bands are much weaker eliminating 
their interference as a major problem. As indicated above, however, Raman signals are 
intrinsically quite weak. Two modified forms of Raman spectroscopy, however, can potentially 
overcome this problem. The first is resonance Raman spectroscopy (RRS). In this method, an 
ultraviolet (UV) laser excites the sample within an absorption band(s). With proteins, this most 
often involves the peptide band itself in the far UV region. The electronic absorption band 
transitions of the peptide bond become coupled to vibrational transitions resulting in a dramatic 
increase in the intensity of the vibrational signals and a much more intense Raman spectrum. 
The two major problems with this approach are the need for expensive UV lasers and the 
degradation of the sample due to the intense, focused UV light. The latter can be at least 
partially overcome by the use of a flow cell. As appropriate instruments become more readily 
available, we expect to see expanded use of this method.  
	 13 
A second technique is known as surface-enhanced Raman spectroscopy. Spectra can be 
enhanced by as much as 1011 – 1012. The sample is usually deposited on a metallic surface such as 
silver or gold, often in the form of a nano- or microparticles. The mechanism is thought to 
involve the electric field of the surfaces and the excitation of localized plasmons. Visible or near 
IR light is used to excite the surface- bonded molecules of interest. The extraordinary sensitivity 
of the method makes it very attractive, but the need for surface localization and the particular 
surfaces which display the necessary properties have so far limited its use in the 
biopharmaceutical world.  
1.2.3 Tertiary Structure-Sensitive Methods  
The precise tertiary structure of a protein can only be determined by X-ray 
crystallography, NMR, or cryo-electron microscopy. A potential 3D structure may also be 
estimated by homology modeling and energy minimization. None of these methods are usually 
directly applicable to protein formulation and stabilization work. Thus, lower resolution methods 
are again typically employed with an emphasis on changes in tertiary elements rather than the 
actual 3D structure itself. Here we will describe the most prevalent of these methods, their 
routine use, as well as their advantages and disadvantages.  
The simplest but not the most widely used method to examine tertiary structure changes is 
UV absorbance spectroscopy12. This method has been widely used to measure protein 
concentration but has been increasingly applied to gather additional information. Below 300 nm, 
proteins primarily display two peaks. One in the far UV arises from peptide bonds (this is the 
same peak used in far CD analysis) and a second from the side chains of the three aromatic 
amino acids with a weak contribution from disulfide bonds. In principle, the far UV peptide 
bond peak found between 180 and 200 nm could be used to analyze secondary structure, but it is 
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poorly resolved, and interference in this region by oxygen and other agents is difficult to 
overcome with conventional spectrometers. Thus, its use has been superseded by CD analysis in 
the same spectral region. In contrast, the near UV aromatic region possesses great utility, which 
we will describe below. All three aromatic side chains feature structured spectra with the 
magnitude of their extinction coefficients in the order Trp > Tyr > Phe. Even a simple visual 
inspection of a protein’s near UV spectra often permits the presence of all three side chains to be 
confirmed if they are present in at least moderate concentration. The high information content of 
a protein’s spectrum can be easily seen by calculating its second derivative, which will typically 
display 7 – 8 distinct negative peaks. Using a diode array instrument and curve fitting (the 
method of splining works especially well), the position of these peaks can often be established to a 
precision of ± 0.02 nm. Since the Phe residues are usually buried, Tyr interfacial due to its 
hydroxyl group and Trp can potentially be found throughout the structure, the derivative UV 
spectrum of a protein can provide significant information about changes in the tertiary structure 
of a protein. Effects of temperature, pH, ionic strength, solutes, and long-term real-time and 
accelerated stability can all be probed (Figure 1.4)13. Furthermore, if light scattering (turbidity) is 
present, this is usually manifested by optical density (OD = absorbance + turbidity) above 300 
nm which is proportional to a high power (3 – 4) of the wavelength (due to Raleigh scattering). 
Note that absorption spectra can be corrected for the presence of light scattering by a variety of 
different methods including extrapolation of OD value above 300 nm into absorbing regions 
(which is nonlinear) and the use of derivatives14. Using temperature-dependent second derivative 
absorbance spectroscopy of aromatic amino acids15 or by analysis of the effects of cation-π 
interactions on absorption16, aspects of protein dynamics can also be probed.  
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Figure 1.4. Bovine granulocyte colony-stimulating factor (bGCSF) is a member of the four helix 
bundle family of proteins and has veterinary therapeutic potential, whereas its human analog is already 
an important drug. Derivative absorbance studies of bGCSF are shown here as a function of temperature 
at pH 5. The wavelength positions of six negative peaks were followed as a function of temperature: (a), 
Phe; (b), Phe; (c), Phe; (d), Tyr; (e), Tyr/Trp; and (f), Trp. Protein concentration was 5 μM in 10 mM citrate 
buffer. Spectra were collected at 2.5 °C intervals, with a 5-min temperature equilibration period included 
before data collection. All errors are reported as standard error (n = 3). (See reference13)  
Probably the most widely used class of methods employed to examine changes in the 
tertiary structure of proteins are those that involve fluorescence spectroscopy17. The origin of the 
fluorescence signal used in pharmaceutical protein development activities can be either intrinsic 
or extrinsic. The intrinsic fluorescence from proteins arises primarily from aromatic residues. If 
Trp is present, this will almost always dominate the emission spectrum since Tyr and Phe are 
weak emitters and can lose energy by energy transfer (see later). If no Trp is present, then the 
fluorescence of Tyr and to a lesser extent Phe can be seen. One exception occurs when the 
emission of the indole side chain is quenched, perhaps by a proximate positively charged amino 
or guanidine group. The effect of temperature on aromatic emission results in a smooth decrease 
due to thermal quenching of the excited state, but this can usually be differentiated from 
structure changes which produce an alteration in the continuous decrease or a change in 
inflection of the curvilinear thermally induced decrease in intensity. Another method to resolve 
structural changes is to measure peak position instead of spectral intensity. Peak position can be 
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accurately determined using derivative analysis or by determining the mean spectral center of 
mass. The latter is usually more precise but is redshifted 8 – 14 nm relative to actual peak 
position because of the asymmetry of Trp fluorescence peak (Figure 1.2e, f, and 5)18.  
The quenching of intrinsic fluorescence can be achieved by extrinsic agents19. The most 
common method employs small molecules such as acrylamide or heavy metal salts, which 
effectively quench some aromatic side chains. A neutral molecule- like acrylamide can actually 
diffuse through the dynamic protein matrix. Varying the concentration of the quencher and its 
effect on quenching can be used to probe the dynamic nature of a protein, although care must be 
taken to ensure the quenching probe does not alter the structure of the protein (especially with 
acrylamide). In contrast, a charged ion such as iodide or cesium can be used to selectively quench 
surface residues (usually Tyr).  
Polarization measurements can also often be of utility in certain applications. When a 
protein is illuminated with polarized UV light, it will selectively excite those fluorophores whose 
absorption transition dipole moments are approximately parallel to that of the incident light. As a 
target fluorophore rotates, the polarization of the emitted light is decreased. From an analysis of 
such data, rotation correlation times of entire molecules can be determined. The rotational 
correlation time is the time required for the molecule to rotate 1/3 of its circumference. Since the 
rotational time is sensitive to the size and shape of a protein, the technique can be used in studies 
requiring such information. Furthermore, when two molecules interact, the rotation of the 
fluorophores is slowed, and the polarization is decreased along with the rotational correlation 
time. In fact, this method is infrequently used during the formulation and development of 
therapeutic proteins but is much more commonly used in a wide variety of binding assays. We 
should mention here that one is not limited to intensity and peak position measurement in 
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fluorescence. The lifetime of the excited state can also be obtained with microtiter formats for 
such determination now available (Figure 1.5).  
 
Figure 1.5. A schematic diagram of a high-throughput fluorescence plate reader (a). This 
instrument is capable of recording both (time-resolved fluorescence) TRF and (steady-state fluorescence) 
SSF. An emission mirror is placed to direct the emission signal to a CCD detector for the measurement of 
SSF. Otherwise, the TRF signal is recorded by a PMT. A general workflow for the formulation optimization 
of proteins using this fluorescence plate reader (b). Thermal melting study of protein samples using 
intrinsic SSF (C1–3) or TRF (D1–3). Representative temperature-dependent raw fluorescence spectra 
(C1) of samples; the processed melting curves are monitored by moment (red dot) or intensity (black dot). 
Fitted melting curves using a six-parameter fitting method are shown as a continuous line (C2). 
Calculation of the melting temperature (Tm) using the first derivative (C3). Representative temperature-
dependent raw waveform (D1) of samples; the processed melting curves are monitored by moment (red 
dot) or intensity (black dot). Fitted melting curves using the six-parameter fitting method are shown as a 
continuous line (D2). Further calculation of the Tm using the first derivative (D3). The dashed lines 
indicate Tm. (See reference18)  
There are, in fact, a remarkable number of experimental approaches that employ 
fluorescence emission. We will very briefly mention a few more of these although most are not 
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commonly employed during the general pharmaceutical development of proteins. Fluorescence 
resonance energy transfer (FRET) is a method that takes advantage of the phenomenon in which 
excitation of a fluorophore (the “donor”) whose emission peak overlaps the absorption peak of a 
second fluorophore (the “acceptor”) can produce a resonant transfer of energy such that the 
excitation of the donor results in a decrease of its emission and the sensitized emission of the 
acceptor. The efficiency of this process is dependent on the distance between the donor and 
acceptor and the angle between their dipoles and their spectra (in the form of a spectral overlap 
integral). In ideal cases, the distance between the donor and acceptor can be calculated. This 
usually involves the use of one or more extrinsic fluorophores covalently attached to known 
locations, a situation not ideal for the pharmaceutical scientist since it could significantly alter the 
size and solution behavior of a therapeutic protein. It is thought, however, that the energy 
transfer between Tyr and Trp residues is partially responsible for the weak emission of Tyr 
residues in most proteins. The technique is, however, widely used in fluorescence microscopy, a 
method of great importance, which we will not consider here. There are a wide variety of other 
fluorescence-based methods not routinely encountered in pharmaceutical analysis. There include 
fluorescence photobleaching and recovery, fluorescence correlation spectroscopy, red-edge 
excitation, and single-molecule fluorescence which might have some utility under special 
circumstances but are more in the realm of the specialist. The use of extrinsic dyes, however, 
opens up a wide variety of methods that are of significant importance to the pharmaceutical 
scientist. We will focus on just a few of these applications here based on their relative importance 
in the analysis of therapeutic proteins.  
Extrinsic fluorescence probes have several advantages over intrinsic fluorophores including 
usually greater fluorescence (quantum yield), large sensitivity to their local environment, and the 
wide variety of such molecules with diverse properties that are available. One such use is the 
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direct binding of probes (often called dyes for historical reasons) to particular regions of both 
native and conformationally altered proteins. Most commonly used probes have at least an 
element of apolar (hydrophobic) character. Thus, if a protein has a site or sites of an apolar 
nature, it is possible that a dye (depending on its structure) may bind to a protein. This is 
especially the case if a protein is partially unfolded or altered in such a way that binding is 
facilitated. For example, molten globular states of proteins which contain near-native secondary 
structure but a loosening of tertiary structure often bind a variety of dyes. Binding can be 
manifested by either an increase or decrease in the intensity of the dye’s fluorescence and/or a 
shift in its emission wavelength optimum. Some dyes are strongly quenched by an aqueous 
environment, and their intensity becomes dramatically enhanced when they are located in an 
environment where their quenching is at least partially relieved. Therefore such dyes can be used 
to characterize the stability of a protein as a function of temperature, the most common 
perturbant. The dyes 8-anili- nonaphthalene sulfonic acid (ANS) and bis-ANS are often used for 
this purpose (Figure 1.2c, d, and 6)4. Other forms of stress (e.g., pH, a chaotropic agent, etc.) can 
be problematic since they can alter the interaction of a dye with a protein independent of 
structural perturbation. In recent years, the availability of PCR instruments in many laboratories 
has led to their use for fluorescence melting studies employing dyes such as SYPRO orange. If 
detergents are present in formulations, there are a class of dyes known as molecular rotors, which 
appear to not bind to detergent and can therefore be used as probes20. It is also possible to 
conjugate fluorescent dyes to proteins where they can serve as conformational or environmental 
probes or as FRET donors and acceptors. In pharmaceutical formulation and development, 
however, this produces a significantly altered protein which cannot be considered an accurate 
representation of a drug substance.  
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Figure 1.6. Normalized ANS fluorescence intensity change as a function of temperature in the 
presence of an untreated (control) IgG1 (black line), partially deglycosylated IgG1 (green line), and fully 
deglycosylated IgG1 (red line) from pH 4 to 6. Normalized results were generated by fitting the data to be 
equal to one at the maxima for incorporation into EPDs and radar charts. Curves shown here are 
averages of three runs. (See reference4)  
Circular dichroism can also be used to examine tertiary structure changes. While the far 
UV region (180 – 250 nm) reflects peptide bond chirality and secondary structure, the near UV 
(250 – 320 nm) contains primarily signals from the aromatic groups and disulfide bonds. These 
spectral features are much weaker than those in the far UV and therefore require higher 
concentrations and longer pathlengths. Typical conditions used might be 0.5 – 1 mg/mL protein 
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and 0.5 – 1.0 cm pathlength. Spectra in this region are not well resolved, but the combined 
intrinsic and induced optical activity make aromatic rings and disulfide bonds quite sensitive to 
subtle changes in their immediate environment. Derivative analysis in the near UV CD region 
can be quite helpful in resolving spectral features, but it is generally difficult to make 
unambiguous assignments other than through the approximate locations of the spectral features. 
Both thermal studies and pH and chaotropic effects can all be explored in this region.  
1.2.4 Quaternary Structure and Protein Aggregation  
Proteins can self-associate into defined oligomers (where the individual proteins are known 
as subunits) or into larger, more random structures which we refer to as aggregates. These higher 
molecular weight entities can be characterized in terms of their size, size distribution, molecular 
weight, and shape among other properties. Such analyses have recently become especially 
important with the recognition of the presence of both submicron and larger particles in 
pharmaceutical formulations of therapeutic proteins. Such aggregates can be both immunogenic 
and display losses of their therapeutic activity requiring their identification and eventual removal 
from final formulations. As a consequence of their all-too-common presence, a wide variety of 
methods have been developed to facilitate their identification and characterization. We do not 
have sufficient space here to describe all such methods currently available, so we will briefly focus 
on the more commonly used techniques and their utility with regard to the formulation and 
development of proteins.  
The most commonly used method to characterize the size of macromolecules, their 
oligomers, and aggregates is size exclusion (molecular sieve or gel filtration) chromatography. In 
this technique, the test solution is pumped through a bed of porous beads made of materials such 
as agarose, dextran, or polyacrylamide.  
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The flow of a protein or other macromolecule is impeded by its diffusion into the beads, 
which is dictated by the size of the channels in the beads and the dimension of the 
macromolecule. The result is a separation of the proteins based on their size, shape, and 
molecular weight with their appearance at the exit of the column detected by their optical 
absorbance, fluorescence (intrinsic or extrinsic), light scattering, refractive index, or some other 
property of the eluted protein (Figure 1.7b)21. It is possible to estimate the molecular weight of 
the chromatographed material by its elution position relative to MW standards, but a more 
accurate value of the hydrodynamic radius can be obtained by this method. Higher molecular 
weight material (e.g., aggregates) usually appears in the void volume of the column since they are 
unable to enter the bead pores and are not separated further. Although this is a very powerful 
method and is widely employed, it does suffer from a couple of potential problems. Proteins are 
diluted as they pass through the column and thus their oligomeric state may change. It is also 
possible that a protein may interact with the column matrix thereby distorting an interpretation 
of its behavior in terms of its size. This can sometimes be eliminated by the addition of high salt 
or a chaotropic agent. There is an alternative separation method that avoids the potential 
problems of inter- action with the column material. This is known as field flow fractionation. 
Here a perpendicular field is applied to sample flowing through a narrow tube. It is especially 
effective for larger particles but can separate proteins, their aggregates, and complexes over a 
very wide range. Although this method has been available for some time, it is usually not as 
readily available as SEC.  
Probably the second most common method to size proteins is dynamic light scattering 
(DLS) (also known as quasielastic or photon correlation light scattering)22. Samples are 
illuminated with a laser, and the scattered light is detected at one or more angles, with 90° the 
most common value. The fluctuations in intensity of the scattered light due to the Brownian 
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motion of the macromolecule or its aggregates are analyzed in the form of an autocorrelation 
function. This can be interpreted in terms of diffusion coefficients and converted to 
hydrodynamic radii by the Stokes- Einstein equation. The usual size range that can be examined 
by this technique is over the range of 1 – 1000 nm. Although a specialist technique, only 20 years 
ago, the availability of commercial instruments has made DLS a routine laboratory method. 
Such instruments are now often employed as “black boxes,” but care is required in their use and 
subsequent data analysis. Because all samples display some degree of heterogeneity, the values 
obtained reflect a range of sizes. Such data can be viewed in a number of different formats 
including in terms of intensity, mass, and number averages. An averaging method known as 
cumulant analysis can provide a “mean” diameter and a measure of polydispersity. Intensity 
deconvolution methods reflect primarily scattering from larger particles and make it appear 
samples are dominated by the larger entities. This can be useful for detecting the presence of 
aggregates but presents a distorted view of the actual particle size distribution in the solution. In 
contrast, the number average calculated distribution reflects the actual distribution and is usually 
recommended if the polydispersity is low. A problem of which to beware is an apparent decrease 
in size at higher concentration. An observation of this type is usually caused by multiple 
scattering. If a photon is scattered more than once, this adds a fast component to the 
autocorrelation function which can be mistaken for a decrease in size. This can be partially 
corrected for by the use of back-scattering angles so the radiation does not penetrate deeply into 
the solution, but this usually is only partially effective. DLS experiments can usually be 
performed as a function of temperature, and the absolute intensity can also be obtained 
simultaneously, adding to the utility of this method (Figure 1.8)23.  
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Figure 1.7 The potential human therapeutic protein pentraxin (PTX-2) is a large, glycosylated 
plasma protein consisting of five monomers that self-associate noncovalently into a pentameric, ringlike 
structure. Determination of the size distribution of rh-PTX-2 in solution. (a) Distribution of sedimentation 
coefficients as determined by sedimentation velocity analytical ultracentrifugation for rhPTX-2 at 0.17 
mg/mL (magenta) and 0.35 mg/mL (red) in PBS buffer and at 0.34 mg/mL in PBS buffer containing 6 M 
urea (black). (b) A SEC chromatogram for rhPTX-2 in 10 mM sodium phosphate pH 7.5 with 5% (w/v) 
sorbitol was generated by dilution into the SEC mobile phase buffer before analysis. Both methods detect 
the subunit structure of the protein. (See reference21)  
Static light scattering (SLS) can be considered of equal importance to the dynamic form24. 
This method has been employed in a variety of forms ranging from the simple to the complex. 
The most sophisticated approach involves measurements of scattering intensities at multiple 
angles and concentrations. The scattering determinations are often in the form of 
chromatography detection on a SEC column and can provide detailed information about the 
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molecular weight and radius of gyration of a protein (Figure 1.9)25. A setup to do this, however, 
can be somewhat expensive. Much simpler but less informative procedures can simply employ 
the scattered light at the excitation wavelength in a fluorescence experiment or the optical density 
(turbidity) from a simple spectrometer. These simple procedures are surprisingly powerful 
approaches which are usually available in a microtiter plate format making it especially useful for 
screening purposes. Whatever the instrument used to obtain such scattering data, it is usually 
used in a relative rather than absolute manner. In a common experiment, scattering intensity or 
turbidity is recorded as a function of time. These values are then analyzed as initial rates, delay 
times (reflecting nucleation events), or final values reached at longer time. When screening for 
inhibition of aggregation, one then looks for a decrease or complete elimination of one or all of 
these parameters. This approach is widely used since aggregation is often a key, undesired event 
in the degradation of therapeutic proteins. One should also not underestimate the utility of 




Figure 1.8. The hepatitis C virus (HCV) envelope glycoprotein E1 has been employed as a 
potential vaccine antigen. A truncated form (amino acids 192 – 326) of the E1 protein (E1y) was 
expressed in the yeast Hansenula polymorpha and purified from the cell lysate. E1y forms protein 
particles in the absence of detergent and remains monomeric when detergent concentration is high. 
Dynamic light scattering (DLS) measurements of HCV E1y (1 mg/mL) in the presence of Empigen BB 
from 10 to 87.5 °C. The DLS intensity at 532 nm was measured at a 90° angle to the incident beam with a 
30-s integration time. The light-scattering intensity is shown in panel (a) for pH 5 and panel (c) for pH 7. 
The effective hydrodynamic diameter is calculated using the cumulant method and presented in panel (b) 
for pH 5 and panel (d) for pH 7. The mean values of five measurements are shown for the following 





Figure 1.9. Illustrative SEC-MALS chromatogram and weight-average molecular weight (Mw) 
profile for an aggregated bovine α-chymotrypsinogen A (aCgn) created by incubating an initially mono- 
mer sample (initial protein concentration, C0 = 1 mg/mL) at 65 °C for 10 min to achieve approximately 
30% (by mass) loss of monomer. A Protein PAK 125 SEC column is used. The peak at ca. 6.5 min is 
high-molecular-weight aggregate; the peak at ca. 8.5 min is monomer. Solid and dotted lines, 
respectively, are relative light-scattering intensity (left vertical axis, only 90° scattering angle shown) and 
relative UV absorbance at 280 nm (right vertical axis). Mw values (scaled by theoretical monomer Mmon 
= 25.7 kDa) for each 1 s “slice” of the two peaks are given by the symbols (lefthand vertical axis). (See 
reference25)  
Recently, it has been recognized that actual colloidal phase separation can also occur. 
While at first this usually appears like the above, with time the solution will actually separate into 
two distinct phases, one much more concentrated in protein than the other. Another observed 
form of precipitation appears as particles or strands of material with a wide range of physical 
properties.  
The preceding are probably the most common methods used to characterize the size, 
oligomeric state, and aggregation of pharmaceutical biomolecules. There has been a recent 
explosion of interest in alternative techniques with individual advantages. We will briefly consider 
four of these. The first is known as micro-flow imaging (MFI). This method directly images 
particles employing a digital camera and measures both counts and size and characterizes 
various aspects of the morphology of the observed entities. To a limited extent, it can 
differentiate different types of particles (proteins, air bubbles, aggregates, etc.) and provide an 
accurate picture of the distribution of sub-visible particle sizes. Depending on the instrument, it 
can measure particle size in the range of 1 – 2 μm to 300 μm. Such instruments have become 
increasingly widely used to characterize protein formulations and their aggregates (Figure 1.10)26.  
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Figure 1.10 Radar plots for visualizing formation of sub-visible particles (concentration and size 
distributions) in IgG1 mAb solutions exposed to different stresses as measured by MFI. Radar plots show 
MFI particle concentration and size data distributions as generated by four indicated stresses when 
applied to a 1 mg/mL antibody solution in 10 mM sodium acetate, pH 5 with and without 150 mM NaCl. 
See reference26 for details of radar plot analysis. The data shown are the average of three separate 
experiments (n = 3), and the error represents one standard deviation. The relative sizes determined by 
MFI are shown as the magnitude of the axes in the radar diagrams (see box). (See reference26)  
A second instrument employs a method known as nanoparticle tracking analysis (NTA). 
This method is effective at determining smaller sizes (10 – 2000 nm) and functions by measuring 
the diffusion of individual particles, in contrast to DLS. Particles are individually observed 
undergoing Brownian motion. Using a camera (e.g., a CCD), the motion of the particles are 
tracked on a frame by frame basis with the Stokes-Einstein equation used to calculate a 
hydrodynamic radius. An accurate particle distribution can be obtained. A third method is 
known as resonant mass measurement. This method employs a micro electromechanical system 
and is usable over the particle size range of approximately 50 nm – 5 μm. It measures both 
particle size and number, but in addition it can be used to determine particle surface areas, 
density, and dry and buoyant mass among other parameters. There are additional methods such 
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as cell-sorting procedures available in addition to the three described above, but in an ideal 
situation, a combination of the methods described above can be used to build an accurate picture 
of a protein, its oligomers and aggregates, and the distribution of the various components and 
their sizes.  
An older approach which is both high resolution and information rich involves the use of 
the analytical ultracentrifuge27. Two different methods are available both with their advantages: 
sedimentation velocity and equilibrium analysis. The instrument employed is a typical 
ultracentrifuge, but it is equipped with an optical device that allows one to directly monitor the 
behavior of a protein or other macromolecule in the presence of a centrifugal force produced by 
the spinning of a centrifuge’s rotor. Special cells are used that permit multiple solutions to be 
monitored as a function of centrifugation time.  
In a sedimentation velocity experiment, the rate at which a macromolecule is sedimented 
down a sector-shape cell is measured. This rate in the form of a sedimentation coefficient (s) is 
measured. This velocity normalized to the centrifugal field strength is directly proportional to the 
molecular weight of the particle after correction for buoyancy and the friction coefficient of the 
protein, both measurable parameters. Such measurements can resolve individual particles to a 
high resolution (Figure 1.7a)21.  
In a sedimentation equilibrium study, the sample is spun at a lower speed until an 
equilibrium concentration gradient of a macromolecule is created within the cell. This gradient 
can be analyzed to yield a molecular weight for a homogenous sample. In the case where an 
equilibrium between species is present, the data can be fit to a variety of association models to 
yield a description of any association which is occurring. Both methods are extremely powerful, 
but sedimentation velocity is the more commonly used method in pharmaceutical analysis. 
Analytical ultracentrifugation is generally not amenable to high-throughput work, and the 
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instrument is expensive, so it is primarily used as a research tool rather than directly in 
formulation development.  
There are a number of other methods that are commonly used in the development of 
protein pharmaceuticals. Of particular importance are those involving calorimetry. Differential 
scanning calorimetry (DSC) is the most widely applied form and is of great importance in 
establishing the thermal stability of proteins. In DSC experiments, the difference in energy (heat 
capacity) required to maintain a sample and reference at the same temperature as the overall 
temperature is varied and measured (Figure 1.11)4. When a molecule undergoes a structural 
transition, an exothermic peak is seen. If the transition is reversible, the area under the peak 
corresponds to the enthalpy of the transition. In some cases, multiple peaks may be observed 
corresponding to the thermal behavior of individual subunits or structural domains within 
individual proteins. If aggregation is occurring, a peak in the opposition direction of a structural 
disrupting peak may be seen, but the design of modern calorimetry cells has reduced or 
eliminated their magnitude. Variation in protein concentration and scan rate can also be used to 
probe protein-protein interactions. High-sensitivity DSC instruments are relatively expensive but 




Figure 1.11. The state of glycosylation of therapeutic proteins (in this case an IgG1) is known to 
have a significant effect on their structure, action, and pharmacokinetics. Shown here is a differential 
scanning calorimetry analysis of untreated (control) IgG1 (black line), partially deglycosylated IgG1 (green 
line), and fully deglycosylated IgG1 (red line) from pH 4 to 6. Normalized heat capacity changes were 
generated by fitting the data to be equal to one at the maxima and to zero at the minima for incorporation 
into the EPDs and radar charts. Curves shown here are averages of three runs. (See reference4)  
Another type of calorimeter is the isothermal titration calorimeter. In these instruments, 
one solution is titrated into another. The most common type of experiment involves the titration 
of a smaller molecule (a “ligand”) into a protein (a “receptor”) solution or vice versa. The heat 
absorbed or released in the titration steps (via a syringe) can be used to obtain the enthalpy, 
entropy, and stoichiometry of binding based on fitting to various binding models. In a similar 
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manner, the binding of one macromolecule to another can be characterized and both the 
thermodynamics and number of binding sites obtained. This is an especially nice method to 
examine excipient/protein interactions if they are reasonably strong. There are other 
calorimetric methods, but one that is occasionally useful to the pharmaceutical scientist is the 
dilution calorimeter in which the dissociation of oligomeric systems can be studied. It should be 
especially noted that lower sensitivity DSC and thermal gravimetric analysis are important in the 
study of protein solids.  
A method that has just come into its own in the last few years is hydrogen/deuterium 
exchange (HDX). A protein is exposed to D2O for various periods of time, and the partially 
exchanged forms are analyzed by enzymatic peptide mapping and mass spectrometry. The rate 
of appearance of labeled peptides serves as a measure of their exposure to solvent and provides a 
picture of the dynamics of a protein. Localized regions of the protein manifesting different 
exchange rates provide peptide level resolution which can be further enhanced to a residue level 
if additional information such as crystallographic temperature factors are available. Thus, the 
binding sites of excipients and “hot spots” of protein association can be localized by this method 
(Figure 1.12)28. Although the instrumentation to perform such studies is expensive due to the 
presence of a mass spectrometer, measurements are so information rich that this is becoming an 
important method for the pharmaceutical scientist. For example, it can be used to localize 
excipient binding sites as well as those of protein/protein interactions29.  
We will conclude with comments concerning three additional methods that are perhaps 
less commonly used but can be important in a number of specific situations. With the advent of 
high-concentration protein formulations (especially those of monoclonal antibodies), the need for 
viscosity measurement has become increasingly important. There are a variety of instruments 
available to measure solution viscosity. A traditional method used in protein chemistry employs a 
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U-shaped hollow tube. These are also known as Ostwald capillary viscometers. The temperature 
of the test solution is tightly controlled, and the time for the test liquid to pass through a fixed 
volume is determined. These instruments are not highly accurate and are rarely used today. In a 
falling sphere viscometer, solid balls (usually steel) are allowed to fall through the medium of 
interest, and the time to reach terminal velocity is measured. Other types include vibrational, 
oscillating and falling piston, Stabinger, and rotational viscometers. Recently a number of new 
methods have come into increased use. The quartz viscometer uses a hollow oscillating quartz 
crystal. The vibration of the sensor causes shearing of an interior fluid which is monitored by an 
electric signal. A recent favorite is the rectangular-slit viscometer usually employing 
microelectromechanical and microfluidic systems. In this method, the pressure drop in the test 
solution is monitored by an array of sensors. The instruments use very small volumes 
(microliters), can measure very high viscosities, and are relatively high throughput (Figure 1.13)30. 
There are many other types of viscometers which may be appropriate for certain applications, 
but the slit types seem to be the current device of choice for high-concentration protein solutions.  
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Figure 1.12. Fibroblast growth factor-1 (FGF-1) is a protein of significant clinical utility. It is 
dramatically stabilized by polyanions. Here isotope exchange was used to establish their binding site, and 
it is clearly seen that it is the same for each polyanion and its location identified. Relative protection of 
FGF-1 peptides by heparin, low MW heparin, phytic acid, and ATP: HX-MS was performed with FGF-1 in 
the presence of (a) heparin, (b) low MW heparin, (c) phytic acid, and (d) ATP. The ΔHX values for each 
FGF-1 peptide are shown and colored according to their k-means categorization: strong protection, deep 
blue; intermediate protection/insignificant, gray. (See reference28)  
As mentioned several times above, the measurement of the density of protein solutions is a 
critical parameter. It is possible to calculate approximate protein densities (and their reciprocal, 
the partial specific volume) from amino acid compositions, but actual measurements are to be 
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preferred. Traditionally, hydrometers have been used which are based on the buoyancy of a 
floating glass body and the depth it sinks in a supporting liquid. Pycnometers simply measure the 
weight of the sample solution in a device of fixed volume. Both methods are simple and 
inexpensive but possess a number of undesirable properties. From the perspective of 
pharmaceutical protein therapeutics, hydrostatic balances are relatively accurate but involve an 
expensive apparatus and a large, complex air-conditioning system. In this method, a sinker is 
placed in the sample, and the apparent weight loss of the sinker is determined.  
In pharmaceutical applications, however, none of these methods are currently used with 
any frequency. They have been replaced by digital density meters. Like several of the methods 
already described, a density meter employs the U-tube principle. A hollow tube is filled with the 
sample liquid. The U-tube is set in a counter mass block and can be set into oscillation. As the 
mass of the liquid increases, the frequency slows allowing the density of the particles in the liquid 
as well their partial specific volume to be determined. With care, this technique is extremely 
accurate and is now usually the preferred method.  
Osmometry is also often used by the pharmaceutical chemist. Once upon a time, this 
method was used to determine molecular weight but has been superseded by many of the 
methods described above, especially mass spectrometry. The osmotic pressure of a protein 
solution is, however, an extremely important property of a pharmaceutical formulation for 
obvious reasons. Thus measurement of this parameter is extremely important. There are three 
common techniques used to measure the osmotic strength of a solution. These are vapor pressure 
depression, freezing point depression, and membrane osmometers. All of these work well for 
determining the total concentration of dissolved salt and sugar among other compounds in 




Figure 1.13. With the advent of high-concentration mAb solution, the need to lower their viscosity 
has become apparent. The effect of the concentration of selected excipients on the solution viscosity of 
175 mg/mL solutions of (a) mAb A and (b) mAb C containing 10 mM histidine at pH 5.75 is shown here. 
MAb A precipitated in formulations containing sodium citrate concentrations of about 25 mM and higher. 
Values are average and SD from triplicate measurements. (See reference30)  
In this brief discussion, we have described many of the major methods (with an emphasis 
on the biophysical) that are used by pharmaceutical scientists to characterize and formulate 
therapeutic proteins. Similar or identical techniques can be used for the development of nucleic 
acid-based pharmaceuticals and many vaccines. It is possible to combine the data obtained from 
such methods to paint a detailed picture of target proteins using methods such as empirical phase 
and radar diagrams. A variety of stresses can be used including temperature, pH, buffer identity, 
agitation, and freeze thaw. Furthermore, as mentioned previously, multiple methods are often 
available in single instruments. For example, CD spectropolarimeters can combine near and far 
UV CD, fluorescence, absorbance, and light scattering. Certain fluorometer can monitor 
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intrinsic and extrinsic fluorescence, lifetime, and scattering data. Thus secondary, tertiary, and 
quaternary (including aggregation) structure can be simultaneously characterized. This can be 
also done in a microtiter plate format allowing the high-throughput acquisition of data. All of this 
together suggests it has become possible to develop and formulate therapeutic proteins with 
increased speed and efficacy.  
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2 Label-free, Direct Measurement of Protein Concentrations 
in Turbid Solutions with a UV-Vis Integrating Cavity 
Absorbance Spectrometer 
2.1 Introduction 
The ability to measure protein concentration is fundamental to protein science. Ultraviolet 
absorption of light by aromatic chromophores (e.g. Phe, Trp, Tyr) and dye binding techniques 
are traditionally used to measure protein concetration1. UV concentration measurements use 
Beer’s law (A = εcl) to relate protein absorbance at 280 nm (A280) to its concentration linearly 
through its extinction coefficient2. Proteins are often paired with relatively large (10 nm – 100 
µm) delivery vehicles or adjuvants, in the case of vaccines, to prolong or enhance their immune 
response3,4. These additional components impose difficulty in protein concentration 
measurement because they can scatter, absorb or emit light which interferes with both UV 
absorption and dye binding measurements. The scattering of light is particularly problematic for 
absorption measurements in typical spectrometers since even minor amounts of scattering 
components may significantly increase solution optical density, which can be incorrectly reported 
as increased absorbance. The intensity of scattered light is proportional to particle size (d) and 
wavelength (λ) as ~d6/λ4 for particles that do not exceed the wavelength of the light (Rayleigh 
scattering). For larger particles the wavelength dependence of scattered light is proportional to 
1/λn where n ranges from 2 to 45. Methods for correction of light scattering artifacts have been 
proposed for situations where light scattering is minimal2. However, for highly scattering 
solutions, the typical geometry employed in spectrometers is not suitable for the measurement of 
optically dense solutions. In many cases, to measure protein concentration, proteins must be 
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separated from particles or fluorescently dyed. A method which can measure protein 
concentration without the need to separate or dye proteins is therefore of great interest.    
Here we propose the use of an integrating cavity absorbance spectrometer to capture and 
quantitate scattered light for protein concentration measurements in turbid media. Integrating 
cavities are coated with a highly reflective material so light entering the cavity is reflected 
multiple times within the cavity before exiting towards the detector. Multiple reflections result in 
an increased effective path length inside the cell and the light measured by the detector is diffuse. 
Light scattered by materials within the cavity also contributes to diffuse measurement light. 
Absorbing materials not only absorb light but also decrease the effective mean path length of 
photons within the cavity, resulting in an attenuated apparent absorbance compared to Beer’s 
law6. Absorption cavity spectrometers were initially developed to measure the absorbance 
coefficients of weakly absorbing samples such as water or methane6,7. More recently, integrating 
cavities have been used to measure the concentration of cellular metabolites such as iron or heme 
in situ8,9. 
We show quantification of protein concentration with an integrating cavity absorbance 
spectrometer is effective for three common protein + adjuvants/carrier systems: Alhydrogel 
(AlOH), gold nanoparticles (AuNPs) and poly lactic-co-glycolic acid (PLGA). These systems 
represent an optically diverse set of conditions: AlOH is purely a photon scatterer, AuNPs 
scatter, absorb and emit photons, and PLGA is another pure photon scatterer. The wide size 
ranges for AlOH (diameter 1 – 10 µm), AuNPs (of diameter 20 nm used here) and PLGA 
microspheres (diameter 20 – 50 µm) employed illustrate the broad applicability of the technique. 
AlOH and AuNPs interact with proteins similarly by adsorbing proteins to their surfaces 
primarily through electrostatic interactions10,11. Also, both AlOH and AuNPs can form covalent 
bonds with proteins, AlOH through ligand exchange and AuNPs through thiol-Au bonds. In 
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contrast, PLGA encapsulates proteins within spherical matrices (pictured Figure 2.S1 in 
Supporting Information), which makes protein concentration measurements impossible without 
complete protein release by solvation of the PLGA scaffold12. 
Alhydrogel is the most commonly used vaccine adjuvant3. There are several methods to 
measure protein concentration while on the surface of Alhydrogel, but these methods require dye 
labeling rendering the sample unusable13,14. Most methods require release of the protein by pH 
or use of a chaotropic agent15. AuNPs are being used for a variety of applications including 
biosensing, bioimaging, therapeutic drug delivery and surface enhanced Raman spectroscopy of 
proteins16. Currently the only method for measurement of protein concentration in the presence 
of AuNPs is by circular dichroism, which is only applicable to relatively small (~10nm) AuNPs17. 
PLGA microspheres represent a case where there are no current methods for measuring the 
protein concentration without destroying the particle to release the protein. Proteins 
encapsulated within PLGA cannot be directly measured or even fluorescently labeled. Therefore, 
general methods which can measure protein concentration in turbid solutions are lacking. Herein 
we demonstrate that protein concentrations can be measured while adsorbed to AlOH, mixed 
with AuNPs or encapsulated in PLGA by using integrating cavity UV absorbance spectroscopy.  
2.2 Materials and Methods 
2.2.1 Materials  
Lysozyme, Bovine Serum Albuminum (BSA) and Alcohol Dehydrogenase (ADH) were 
purchased from Sigma-Aldrich (St. Louis, MO). The IgG1 monoclonal antibody was received 
from Janssen. Alhydrogel was purchased from Brenntag (Mülheim, Germany). Buffer 
components (histidine and HEPES) were also purchased from Sigma-Aldrich (St. Louis, MO). 
Poly (D,L-lactide-co-glycolide) (PLGA, 85:15 lactide:glycolide, acid end group, I.V. = 0.48 dL/g, 
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Tg, = 47.3 °C, M.W. = 62 kDa, P.I. = 1.7, Lot #LP831) was purchased from Evonik Industries 
(Essen, Germany). Poly (vinyl alcohol) (PVA, 88% hydrolyzed, M.W. = 20 - 30 kDa, Lot 
#A0320092) was obtained from Sigma Aldrich (St. Louis, MO). Methylene chloride was sourced 
from Fisher Chemical (Certified ACS, Lot #141990, Pittsburgh, PA). 
2.2.2 PLGA Microsphere Synthesis 
Protein-free microspheres, and microspheres containing BSA and lysozyme, were 
manufactured by Orbis Biosciences (Lenexa, KS) using a proprietary process. Briefly, 900 mg of 
PLGA was dissolved in 10 mL methylene chloride. BSA (100 mg) or lysozyme (100 mg) was then 
solubilized in DI water (pH = 6.8) at a concentration of 200 mg/mL. The albumin solution was 
then added dropwise to the PLGA solution, then sonicated over ice for 30 s to create an emulsion 
with a water:oil ratio of 1:20. The emulsion was processed through a pulseless flow pump 
(Harvard Apparatus PHD Ultra, Holliston, MA) and vibrating nozzle system with co-axial DI 
water stream, into a beaker containing a 2000 mL aqueous solution of 0.5% w/v PVA. After 
fabrication, the microspheres were allowed to harden in the collection beaker with stirring at 75 
rpm for 3 h. The microspheres were isolated by suction filtration over a 22 µm filter (Whatman, 
Plc., Filter No. 541, United Kingdom), washed twice with DI water and then placed at –80 °C 
for 2 h. Lastly, the microspheres were lyophilized for 48 h at –38 °C and 0.038 mBar (Labconco 
Freezone 1, Kansas City, MO). The theoretical protein content for both albumin and lysozyme 
groups was formulated to be 10% w/w. PLGA-only microspheres were produced using the same 
manufacturing process. Electron microscopy was performed to confirm PLGA microsphere size 
and loading and shown in Figure 2.S1. 
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2.2.3 PLGA Microsphere Encapsulation Efficiency 
10 mg of PLGA microparticles were dissolved into 750 µL dimethyl sulphoxide (DSMO) 
for 1 h then further diluted with 2 mL 0.5% SDS/0.02 N NaOH for 1 h. Concentrations were 
then determined with a micro BCA assay. Protein content in the BSA PLGA microspheres, as 
determined by µ-BCA, was 0.56 ± 0.2 % w/w. Similarly, the lysozyme PLGA microspheres were 
found to have a protein content of 1.26 ± 0.3 % w/w. This indicates poor encapsulation 
efficiencies of protein into the PLGA particles. This phenomenon can be attributed to the 
microsphere manufacturing process in which the oil-in-water emulsion is initially collected in a 
large aqueous phase. Given the solubility of albumin and lysozyme is favorable under such 
conditions, some diffusion of these species from a hardening PLGA matrix is likely and should be 
anticipated. 
2.2.4 AuNP Synthesis 
Sodium citrate (2.2 mM, 150 mL) placed in a 250 mL flask was heated on a hot plate with 
vigorous stirring. After boiling, HAuCl4 (50 mM, 0.5 mL) was added and the resulting mixture 
was boiled for 10 min until a pinkish color was observed. The flask was then transferred to a 
water bath maintained at 90 °C and equilibrated for 5 min. HAuCl4 (50 mM, 0.5 mL) was again 
added. After 30 min, the reaction was stopped. The size and absorption λmax of the resulting 
AuNP were found to be 21.1 ± 2.9 nm by dynamic light scattering and 522 nm, respectively. 
The optical density (OD) of the AuNPs in this text refers to their OD at 522 nm as measured by 
conventional UV-Vis absorbance spectroscopy. 
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2.2.5 Conventional UV-Vis Absorbance Spectroscopy 
Absorbance measurements were made using an Aligent 8453 UV-Vis spectrometer. 
Spectra for protein concentration measurements were acquired for 2 s. All concentrations were 
measured in triplicate. 
2.2.6 Calibration Curve Preparation 
AlOH and AuNPs were prepared at 2x the concentration used in experiments. Proteins 
were similarly prepared at 2x the concentrations used in experiments. Proteins and AlOH or 
AuNPs were then physically mixed (1:1 v/v) and allowed to equilibrate 1 h before measurement. 
The fraction of protein bound to AlOH was determined after centrifugation by measuring the 
A280 of the supernatant. For the highest concentration of AlOH (2 mg/ml), all of the protein 
(>95%) was determined to be bound to AlOH. For lower concentrations of AlOH (0.2 & 0.02 
mg/ml), the percentage bound varied with the protein concentration and the specific protein 
(IgG or Lysozyme). AuNP concentrations were determined with optical densities (OD) at 522 nm 
as measured by conventional UV-Vis absorbance measurements. For PLGA, protein 
concentrations were determined by weighting the PLGA particles and using the calculated 
encapsulation efficiencies to calculate concentrations.  
2.2.7 Integrating Cavity Absorbance Spectroscopy 
A CLARiTY VF integrating cavity spectrometer (Olis, Inc., Bogart, GA) was used to 
collect spectra. This instrument has two deuterium lamps which illuminate the integrating cavity. 
The integrating cavity has four ports, two for sample illumination by the deuterium lamps, one 
port focused on the monochromator and the fourth port for sample loading.  Spectra were 
acquired from 250 to 350 nm every 2 nm with an integration time of 0.2 seconds. Proteins were 
measured at 5 concentrations at half dilutions (1, 1/2, 1/4, 1/8, and 1/16x) ranging from an 
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A280 of 1 to 0.06. All experiments were performed in triplicate at 25 °C. A small spherical 
magnetic stir bar was placed inside of the cavity for continuous sample mixing. Spectra were 
acquired by blanking the spectrometer with a corresponding reference (e.g. AlOH, AuNPs) at the 
same concentration used with the protein samples. PLGA samples were blanked with water and 
spectra were normalized by subtraction of their absorbance at 340 nm.  
2.2.8 Data Processing 
All data were fitted to an empirical and theoretical relationship between the apparent 
absorbance (𝐴′), as measured with the integrating cavity, and A as measured from the 
conventional UV-Vis spectrometer, as proposed in equation 120: 
𝐴′ = 𝑎! ln(1 + 𝑎"𝐴) 
Where a0 and a1 are empirical constants. All concentration curves (20 curves, 5 points 
each) were fitted with two parameters for each equation - a0 and a1. All equations were fitted 
using a Levenberg-Marquardt algorithm to minimize χ2 20. Confidence intervals of fitted 
parameters were calculated with an F-test as described20. The error of measurements and fitted 
parameters were propagated to the errors on the corrected absorbance (shown as 95% CI error 
bars in Fig. 3). All data was processed with custom scripts written in python using the scipy 
package libraries and matplotlib for visualization21,22. 
We compared the empirical model (eq. 1) to the theoretical model developed by Fry et al.20 
(rearranged from eq. 6 of that work) as shown by equation 2: 
𝐴′ = − 𝑙𝑜𝑔 0
𝑒𝑥𝑝	[−𝐴 ∗ 𝐿#$$](1 − 𝐾)
1 − 𝐾 ∗ 𝑒𝑥𝑝	[−𝐴 ∗ 𝐿#$$]
9 
Where Leff is the effective pathlength of the integrating cavity, and K is a constant which 
represents the cavity reflectivity multiplied by the fraction of the cavity not containing ports. Leff 
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and K were fit similarly to a0 and a1 from the main text with the additional constraint that K was 
bound between 0 and 1. 
2.2.10 Model Comparison 
Statistical differences between the models were compared using the sum square errors 
(SSE) and the Mean Absolute Percentage Error (MAPE) 









Where Ai is the true concentration and Pi is the predicted concentration.  
2.2.11 Limit of Quantitation (LOQ) and Limit of Detection Determination (LOD) 
The LOQ and LOD were determined by measuring 10 blanks, converting the apparent 
absorbance to conventional absorbance, multiplying absorbance by the slope of the linear 
calibration curve (to get units of protein concentration), and taking 10x the standard deviation for 
the LOD and 3.3x the standard deviation for the LOQ.  
2.3 Results and Discussion 
To test the ability of the integrating cavity spectrometer to measure protein concentrations 
in the presence of scattering materials, proteins were mixed, adsorbed or encapsulated with 
scattering components at known concentrations. For clear non-scattering solutions, the spectra 
have overall similarity to spectra measured with a conventional UV spectrometer although the 
spectra are compressed because of the nonlinear response of the integrating cavity. As shown in 
Figure 2.1, the measured absorbance becomes stronger as the concentration of protein increases 
in the presence of AlOH, AuNPs or PLGA. This indicates that an integrating cavity spectrometer 
could be used for protein concentration determination assuming the data could be fit to a model. 
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There have been several models proposed to convert between the absorbance measured 
with a conventional UV spectrometer and an integrating sphere UV spectrometer18,19. The 
empirical model described above makes no assumptions about the shape of the cavity or its 
contents. Initially, we compared this model with a theoretical model which makes assumptions 
both about the shape and contents of the cavity. The error associated with the theoretical model 
was worse in all cases (Table 2.S1, 2.S2, 2.S3). The mean absolute percentage error was 3.1% for 
the empirical model and 6.1% for the theoretical model. While the average errors are relatively 
low for both models, there were some cases (e.g. high AuNP concentrations) in which the 
theoretical model (eq. 2) performed markedly worse. For these reasons we use of the empirical 
model (eq. 1) for calculation of limit of quantification (LOQ) and limit of detection (LOD). 
To measure the protein content of vaccines containing AlOH, fluorescence methods have 
been commonly used. For example, the ninhydrin or o-phthalaldehyde assays are used for the 
fluorescence staining of proteins adsorbed to AlOH13,14. Figure 2.2A, B show that the response 
curve of lysozyme and an IgG have different responses to the amount of Alhydrogel in solution. 
For lysozyme, all concentrations of AlOH produced virtually identical apparent absorbance vs 
concentration curves. For the IgG, as the AlOH content increased, so did the apparent 
absorbance at equivalent protein concentrations. We attribute this increase in apparent 
absorbance to be a protein specific effect because it only occurred with IgG. It is possible that 
upon adsorption to AlOH, the local environments of the aromatic amino acids change which 
causes an increase in its extinction coefficient23. The corrected absorbance concentration curves 
for Alhydrogel have near identical linearity and error as protein in transparent solutions as shown 
in Figure 2.3A, B. 
Protein concentration measurements in the presence of AuNPs are more difficult since 
AuNPs simultaneously scatter, absorb, and emit photons, as well as quench the fluorescence of 
	 50 
proteins. One recent method suggests circular dichroism can be used to measure the 
concentration of protein – AuNP mixtures24. The AuNPs used in that work are ~10 nm, which 
are below 1/20th of the wavelength of light used which is commonly thought of as the limit of 
isotropic scattering25. AuNPs above this size (hundreds of nanometers) are often used and there is 
no direct method for measuring protein concentrations in their presence. Figures 2.2C, D show 
the response of ADH and BSA concentration curves to different amounts of AuNPs. For both 
proteins the apparent absorbance response is diminished with increasing gold concentration. The 
change in response can be accounted for as either a change in effective path length, surface 
reflectivity of the cavity, or absorption coefficient.  We believe this attenuation can be attributed 
to a decreased effective path length as the high concentration of AuNPs has a higher absorbance. 
It has been demonstrated that the mean path length of light travelling through media is 
independent of light scattering26. It has also been shown that for BSA/AuNP mixtures, the 
absorbance and scattering cross section of AuNPs increase with increasing BSA concentration17. 
These considerations make the exact mechanism difficult to assign to solely one contributor. 
Alternatively, a change in reflectivity of the integrating cavity surface because of nonspecific 
adsorption of AuNPs could also be the reason for the decreased sensitivity. The loss of sensitivity 
at high protein concentrations manifests as increased error bars on Figures 2.3C, D with 
increased AuNP concentrations. 
Measurement of PLGA microspheres was made increasingly difficult by the fact that there 
was not a direct method for measuring the calibration curve. As opposed to AlOH and AuNPs, 
where the blank buffer contained the scattering species, the PLGA solutions were blanked against 
a transparent solution containing the buffer. Also unlike the AlOH and AuNPs, the PLGA 
microspheres were not a stable suspension and were therefore allowed to settle (for ~2 min) in the 
cavity before measurement. The concentration curves for both BSA and Lysozyme encapsulated 
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PLGA were attenuated similarly to the high concentration of AuNPs (Figure 2.2E, F). 
Nonetheless, protein concentrations were accurately quantified with the integrating cavity 
method (Figure 2.3E, F). To our knowledge, this is first reported method for a non-destructive 
measurement of protein concentration in PLGA microspheres.  
To increase the utility of integrating cavity spectrometers, the ability to measure second 
derivative spectra in turbid media is of great interest. Attempts to interpret second derivate 
spectra for analysis of individual amino acids were unsuccessful (data not shown). This was 
attributed to inadequate signal-to-noise for quantitation of second derivative peak shifts which 
can be as small as ± 0.01 nm. Increased signal-to-noise could be achieved with a larger 
integrating cavity (increased path length) or more sensitive multiwavelength detector (multiplex 
advantage). Measurements of even lower concentrations (ng/ml) could theoretically be achieved 
with a light source which reaches into the deep UV at 205 nm27. More immediately applicable 
uses of this experimental setup include measurement of DNA or RNA encapsulated in lipids or 
any of the wide variety of nano/microparticle currently being investigated.  
2.4 Conclusion 
A label-free, direct approach to measure protein concentrations in turbid solutions was 
developed using an integrating cavity spectrometer. Adequate robustness of this method was 
shown with proteins in three model turbid systems, Alhydrogel, gold nanoparticles, and PLGA 
microspheres. Using calibration curves fitted to a simple nonlinear model, we were able to 
quantify protein concentrations in a broadly applicable manner. Our study presents a direct and 
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2.6 Figures and Tables 
 
Figure 2.1. Four model proteins used in this study in various conditions. A) BSA in solution B) IgG 





Figure 2.2. Fitted curves of protein A280 values observed using the integrating cavity. Five points were 
used to fit each curve. Error bars represent 95% confidence intervals on triplicate measurements. A) 
Lysozyme on AlOH B) IgG on AlOH C) BSA with AuNPs D) ADH with AuNPs E) Lysozyme encapsulated 





Figure 2.3. Comparison of empirically corrected absorbance spectra to conventional absorbance 
spectrometer. Error bars represent 95% confidence intervals on predicted absorbance. Gray lines 
represent A = εcl for each protein. Panels show A) Lysozyme on AlOH B) IgG on AlOH C) BSA with 




Figure 2.S1. Representative TEM images of PLGA microparticles. A) Empty microparticles B) 





Figure 2.S2. Concentration curves fitted using the theoretical relationship derived by Fry et al.21, 
five points were used to fit each curve. Error bars represent 95 % confidence intervals on triplicate 
measurements. A) Lysozyme on AlOH B) IgG on AlOH C) BSA with AuNPs D) ADH with AuNPs E) 





Figure 2.S3. Comparison of theoretically corrected absorbance spectra to conventional 
spectrometer. Error bars represent 95% confidence intervals on predicted absorbance. Gray lines 
represent A = εcl for each protein. An * denotes error bars were not shown for these measurements, 95% 
confidence intervals gave values with nonphysical meaning (reflectivity above 1 or negative effective 
pathlength). Panels show A) Lysozyme on AlOH B) IgG on AlOH C) BSA with AuNPs D) ADH with AuNPs 




Table 2.S1. Comparing the theoretical and empirical fits for the highest concentration measured 
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Table 2.S2. True concentrations (µg/ml) and predicted concentrations for both the empirical and 
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Table 2.S3. Sum square error (SSE) and Mean Absolute Percentage Error (MAPE) for empirical 










Lysozyme in 10 
mM His pH 6 1.52E-05 1.73E-05 2.0 2.1 
Lysozyme with 0.02 
mgml AlOH 1.48E-05 1.91E-05 1.3 1.5 
Lysozyme with 0.2 
mgml AlOH 3.47E-05 5.14E-05 2.9 2.6 
Lysozyme with 2 
mgml AlOH 1.06E-05 1.62E-05 3.1 2.8 
IgG in 10 mM His 
pH 6 3.81E-04 3.89E-04 4.0 4.1 
IgG with 0.02 mgml 
AlOH 3.67E-05 4.34E-05 2.4 2.5 
IgG with 0.2 mgml 
AlOH 7.74E-05 1.18E-04 2.8 3.1 
IgG with 2 mgml 
AlOH 2.64E-05 1.68E-04 1.1 1.8 
 BSA in 5 mM 
Hepes pH 8 5.44E-04 5.91E-04 2.9 3.1 
BSA with GNP (OD 
0.05) 2.23E-04 8.49E-04 1.6 1.9 
BSA with GNP (OD 
0.2) 2.22E-04 7.37E-03 1.0 4.8 
BSA with GNP (OD 
0.8) 8.50E-04 8.30E-02 6.2 23.2 
ADH in 5 mM 
Hepes pH 8 2.95E-04 4.16E-04 2.9 2.6 
ADH with GNP (OD 
0.05) 8.72E-05 9.81E-05 1.4 1.5 
ADH with GNP (OD 
0.2) 1.24E-04 3.60E-04 3.1 5.6 
ADH with GNP (OD 
0.8) 4.68E-04 1.07E-02 4.8 20.5 
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Lys in PLGA 7.44E-04 6.82E-04 7.9 7.6 
Lys in 10 mM His 
pH 6 2 6.86E-04 9.50E-04 3.9 5.6 
BSA in PLGA 1.62E-04 1.85E-02 3.4 20.1 
BSA in 10 mM His 1.46E-03 2.15E-03 3.8 4.7 










Lysozyme in 10 mM His pH 6 1.4 0.4 
Lysozyme with 0.02 mgml 
AlOH 3.6 1.2 
Lysozyme with 0.2 mgml AlOH 2.8 0.9 
Lysozyme with 2 mgml AlOH 3.5 1.2 
IgG in 10 mM His pH 6 2.8 0.9 
IgG with 0.02 mgml AlOH 6.2 2.1 
IgG with 0.2 mgml AlOH 4.9 1.6 
IgG with 2 mgml AlOH 5.5 1.8 
BSA in 5 mM Hepes pH 8 5.6 1.8 
BSA with GNP (OD 0.05) 9.5 3.1 
BSA with GNP (OD 0.2) 20.4 6.7 
BSA with GNP (OD 0.8) 45.6 15.0 
ADH in 5 mM Hepes pH 8 2.7 0.9 
ADH with GNP (OD 0.05) 4.4 1.5 
ADH with GNP (OD 0.2) 9.1 3.0 
ADH with GNP (OD 0.8) 23.4 7.7 
Lys in PLGA 3.1 1.0 
Lys in 10 mM His pH 6 2 1.3 0.4 
BSA in PLGA 4.3 1.4 




3 Comparison of Polysorbate 80 Hydrolysis and Oxidation on 
the Aggregation of a Monoclonal Antibody 
3.1 Introduction 
Polysorbate 20 and 80 are commonly used in protein therapeutics to prevent nonspecific 
adsorption of proteins to interfaces. Polysorbates owe their widespread prevalence to their ability 
to inhibit aggregation of proteins, possibly by preventing accumulation and subsequent 
aggregation of proteins at the interface. Polysorbate 80 (PS80) is a non-ionic surfactant with a 
critical micelle concentration (CMC) of 0.0017% (wt/v)1. The main species of PS80 contains a 
sorbitan head group with four chains of polyoxyethelyne (POE) extending from it. Theoretically, 
there are a total of twenty POE units which are attached to each head group, although in 
practice there may end up being more or less. Typically there is a Gaussian-like distribution in 
the number of POE units, resulting in a heterogeneous mixture. Of the four POE groups 
attached to the sorbitan head groups, one to three of them are esterified to fatty acids (FAs) at 
their ends which can also terminate in a primary alcohol. The fatty acids found in PS80 are 14 to 
18 carbons long and can have up to three double bonds along the chain. The most abundant 
fatty acid is oleic acid (≥58%, 18 carbons, 1 double bond), followed by linoleic (≤18%, 18 
carbons, 2 double bonds). The number of fatty acid substitutions on an individual sorbitan head 
group can range from zero to four. PS80 also has isosorbide head groups with zero to two fatty 
acid substitutions. There also exists a significant amount of POE-FAs unattached to the head 
groups. All of these components result in a diverse heterogeneous mixture which can vary 
extensively between manufacturers.  
Due to its surface activity as well as small size, PS80 competes with surface active proteins 
such as monoclonal antibodies for the interfacial surface area2. By preventing protein surface 
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adsorption, polysorbates decrease high local interfacial protein concentrations as well as 
adsorption-mediated conformational perturbation3,4. However, PS80 has been known in several 
cases to increase aggregation of quiescent proteins5. This is thought to be the result of specific 
interactions between polysorbate and proteins (e.g. stabilizing unfolded conformations)6. 
Although PS80 is added to prevent degradation of active pharmaceutical ingredients, PS80 itself 
is susceptible to degradation. There are two primary pathways through which polysorbate 
deteriorates, hydrolysis of the ester and oxidation.  
 Hydrolysis of the ester bond in PS80 can be promoted by heat, and catalyzed by acid, 
base, or enzymes such as esterases and lipases7. Enzymatic hydrolysis has been recognized as a 
primary pathway occurring in high concentration antibody formulations. Esterases and lipases 
from host-cell lines can degrade polysorbate at nanogram/mL levels, which may be under 
prescribed protein impurity limits in protein production processes. Phospholipase B-like 2 
(PLBD2) has been identified as hydrolyzing polysorbates at concentrations as low as 200 ppm. 
To prevent polysorbate hydrolysis, Regeneron has developed a genetically modified host-cell line 
in which they engineered downregulation of PLBD2 expression8. Engineering out specific lipases 
can be effective, though identification of the exact enzyme(s) responsible may sometimes prove 
difficult9. The myriad of distinct species which make up PS80 also have different susceptibilities 
to degradation10. For instance, some esterases show preference for shorter fatty acid chains or less 
substituted head groups because of steric hindrance11. Regardless of the component degraded, 
free fatty acids are generated through ester hydrolysis (Figure 3.1). Free fatty acids have been 
implicated as initiating particle formation and identified within aggregates using FTIR 
microscopy12,13.  
 Oxidation is the second primary route of PS80 degradation, with polysorbate 
heterogeneity playing a key role. Polysorbate can be oxidized through exposure to light, by trace 
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peroxides leftover from manufacturing, or by transition metals. The unsaturated fatty acid esters 
are more susceptible to oxidation than their saturated counterparts14. The increased susceptibility 
to oxidation with an increasing number of double bonds stems from the stabilization of carbon-
centered radicals generated by hydrogen abstraction from either allylic of bisallylic methylene 
groups. Figure 3.1 depicts a number of prominent degradation pathways for PS80. Oxidation of 
the double bond can occur in the case of oleic acid or other poly unsaturated fatty acid tails. 
Ultimately, oxidation results in the formation of peroxides, aldehydes, ketones and epoxides. 
Oxidation can also occur on the POE chain, which can result in POE-FA species in the case of 
substituted POE groups or in PS80 with a decreased number of POE substitutions for the 
unsubstituted POE groups10. Intermediary radicals generated from polysorbate can oxidize 
therapeutic proteins, for example at methionine and tryptophan residues5,15. This can result in 
alterations of protein higher order structure and generate oligomeric species. 
In this work, PS80 is subjected to forced oxidation by AAPH and hydrolysis by Candida 
Antarctica lipase B (CALB). PS80 degradation is quantified with mass spectrometry to determine 
the fraction of native polysorbate species intact. A Langmuir trough is used to compare effects of 
degradation on the surface activity of the surfactant. A monoclonal antibody (mAb F) which 
previously exhibited microparticle formation during formulation was chosen to determine the 
effects of PS80 degradation on protein aggregation. Mab F was mixed with the degraded 
surfactants and subjected to shaking as mechanical stress. HPLC-SEC, MFI and visual inspection 
are used to examine the resulting aggregation. After hydrolysis, PS80 containing protein solutions 
resulted in increased particle counts and increased monomer loss as compared to controls. MFI 
morphological features differentiated particles formed in the presence of hydrolyzed PS80 as 
being larger and having higher aspect ratios than particles in the absence of PS80. However, 
even after extensive oxidation of PS80, mAb F retained similar levels of monomer to unstressed 
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PS80 following shaking.  Thus, the current study demonstrates that PS80 hydrolysis and 
oxidation have distinct impacts on protein aggregation. 
3.2 Materials and Methods 
3.2.1 Materials 
 The monoclonal antibody (mAb F) was provided by Astra Zeneca (Gaithersburg, MD, 
USA). MAb F was dialyzed into 20 mM histidine buffer at pH 6.0 at a concentration of 10 
mg/mL preceding accelerated degradation. PS80 was purchased from J.T. Baker (Radnor, PA) 
and diluted in water to a concentration of 10% (wt/v). 
3.2.2 Polysorbate Forced Degradation 
 PS80 was degraded in water at a 1% (wt/v) concentration. Candida Antarctica lipase B 
(CALB) immobilized on immobead 150 was purchased from Sigma Aldrich (St. Louis, MO, 
USA). A concentration of 1.5 U/mL was spiked into a 1% (wt/v) PS80 stock solution. The 
solution was mixed using a rotating mixer for 18 h. Following hydrolysis the solution was filtered 
with a 0.5 μm PES filter to remove the enzymatically coated beads. This solution was stored at 4 
°C in an amber bottle under nitrogen until further use. 
 PS80 (1%) containing solutions were spiked to a concentration of 10 mM 2,2'-azobis(2-
amidinopropane) dihydrochloride (AAPH). Solutions were placed in Pyrex tubes capped with 
rubber stoppers. Solutions were irradiated for 6 h in a Rayonet system (Southern New England, 
Brandord, CT, RMA-500) with four phosphor coated low pressure mercury lamps with λmax of 
350 nm (RPR-3500A). This solution was stored at 4 °C in an amber bottle under nitrogen until 
further use. 
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3.2.3 UPLC-MS Analysis of PS80 and its Degradants 
The separation of PS80 species and their degradants was performed using a PrevailTM C18 
(Grace, Deerfield, IL) column with 150 mm × 2.1 mm dimension, 300 Å pore-size and 3.0 µm 
particles. The column temperature was maintained at 40 °C. One µg of samples were passed to a 
Waters Q-TOF Premier mass spectrometer (Milford, MA, USA) at a flow rate of 0.3 mL/min. 
Four solvents with different elution strength were used to elute the samples from the column; 
solvent A contained 20 mM ammonium formate and 0.08% formic acid in MilliQ water, solvent 
B was 30% methanol, 70% acetonitrile and 0.08% formic acid (v:v:v), solvent C was isopropanol, 
and to wash the column, solvent D with higher elution strength was prepared with 10% dioxane 
and 90% acetone (v:v). The PS80 species and its degradants were eluted with a starting gradient 
of 40% solvent A and 60% solvent B for 15 min and was then changed to 1% solvent A and 99% 
solvent B. At 20 min, 5% solvent C was introduced with 1% solvent A and 94% solvent B. At 21 
min, the solvent gradient was set to 1%, 90% and 9% of solvent A, solvent B, and solvent C, 
respectively and was kept for 3 min. The column was washed with 1% solvent A and 99% 
solvent D for 3 min and at 28 min the column was equilibrated back to 40% solvent A and 60% 
solvent B for 4 min. The total run time was 32 min. 
The UPLC was connected to a Water Q-TOF Premier (Milford, MA, USA) equipped with 
an electrospray ionization source. The samples were run in MSE method, a data independent 
acquisition (DIA) mode, to record full scans in first function. PS80 species and its degradants 
were identified in a positive mode. The MS lenses were calibrated in positive ion mode using 
sodium iodide. The instrument was operated with source temperature at 120 °C, capillary 
voltage of 2.8 kV, and argon as a collision gas at a flow rate of 0.35 mL/min. Masslynx v.4.1 
software was used to control the MS settings and analyze the data. Extracted ion chromatograms 
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with a mass window of 0.1 Da were used to quantify the relative amounts of polysorbate 80 
components in stock and degraded solutions.  
3.2.4 Langmuir Trough 
 A Langmuir trough was used to quantify the surface pressure isotherms for PS80 and 
mAb containing components. Solutions of mAb F were made at 1 mg/mL with a PS80 
concentration of 0.001 % (wt/v). Stock solutions of the different PS80 solutions, without the mAb 
were also run as controls, to study the effect of the two different degradation pathways on the 
surface activity of the PS80. 40 mL of solutions containing PS80 and proteins were dispensed 
into a Langmuir trough (Biolin Scientific, Inc, Stockholm, Sweden). Prior to use, the Langmuir 
trough was calibrated using water. Samples were dispensed quickly and immediately recorded to 
measure the adsorption to the air water interface. A paper Willhelmy plate was used to measure 
surface pressure over the course of two hours.  Initial rate of change of surface pressure was 
calculated by fitting the first two minutes of the data to a linear equation and calculating the 
slope. 
3.2.5 Critical Micelle Determination with Pyrene Fluorescence 
Pyrene (Sigma Aldrich) was dissolved in DMSO and then spiked into PS80 at a 
concentration of 1 uM. Solutions of PS80 were prepared from 0.1% to 4.88*10-5% by two-fold 
serial dilutions. Fluorescence was measured at 25 °C using a Photon Technology International 
(PTI) spectrofluorometer (Lawrenceville, NJ) equipped with a turreted four-position Peliter-
controlled cell holder and xenon lamp. Pyrene was excited by light at 335 nm and emission 
observed at 373 nm and 384 nm with an integration time of 5 s. The ratio of the fluorescence 
intensity of these two wavelengths (l1/l3) was fit to a Boltzmann-type sigmoid as described 
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previously16. The fit was performed using in-house python scripts and the midpoint of the 
sigmoid corresponds to the CMC. 
3.2.6 Mechanical Agitation Studies 
 Solutions of mAb F were transferred to 1 mL vials filled with 0.5 mL of 10 mg/mL mAb 
F in 20 mM histidine and capped with stoppers. Ten samples in total were run in duplicate 
during the shaking study. For each PS80 (stock, hydrolyzed, oxidized) samples were mixed to 
have a final concentrations of 0.01, 0.001, and 0.0001% (wt/v). The tenth sample was mAb F in 
the absence of PS80. Vials were placed on their side on a room temperature (22 °C) HS260 
shaker (IKA Works, Inc., Wilmington, NC) for up to one week at a constant speed of 300 rpm. 
Vials were pulled at five time points (2 h, 8 h, 1 d, 3 d, 1 wk) for analysis by HPLC-SEC and 
MFI.  
3.2.7 HPLC-SEC 
SEC was performed using a HPLC instrument (Shimadzu, Kyoto, Japan) equipped with a 
photodiode array. The mobile phase was composed of 0.2 M sodium phosphate buffer (pH 6.8). 
Prior to injection on the HLPC, samples of mAb F were centrifuged at 13,000 xg for 10 min and 
the supernatant was diluted to 1 mg/mL prior to injection. Injections of 20 μL into a TSKgel 
SWXL guard columns (6.0 mm x 40 mm) followed by a TSKgel G3000Wxl stainless steel 
column (TosohBiosciences, Japan). Following this, the column was removed and twenty 
microliters of sample injected to quantify recovery for each sample. The SEC monomer peak 
area describes is the total area of the monomer peak quantified with absorbance at 280 nm. The 
SEC % monomer represents the fraction of the SEC trace which corresponded to the monomer 
peak. 
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3.2.8 Particle Flow Imaging 
 An MFI 5200 (Protein Simple, Santa Clara, California) flow imaging microscope was 
used to quantify particles generated during mechanical agitation. The instrument was flushed 
with 0.2 μm filtered water until a baseline of below 300 particles per mL was achieved. The 
instrument was focused with NIST traceable 25 μm Duke Standards (Thermo Fisher Scientific, 
Waltham,MA) prior to measurements. Samples of mAb F were diluted 10X (1 mg/mL) prior to 
flow imagining and run in duplicate. A volume of 1.5 mL was analyzed at a flow rate of 0.2 
mL/min and capture speed of 21 frames/s. Particles only partially imaged (edge particles) were 
excluded from analysis. A range of 2 – 100 μm (diameter) was used to quantify the total number 
of particles in each sample. Particle morphology was assessed using in-house python scripts. A 
two dimensional histogram with 50 bins linearly spanning particle sizes from 2 – 100 μm and 50 
bins from aspect ratios of 0 – 1 was used to calculate the number of particle in each of the 2500 
bins.  
3.3 Results  
3.3.1 Polysorbate 80 Degradation and Quantitation 
 Following degradation by a lipase or oxidation, PS80 degradation was quantified using 
mass spectrometry. Figure 3.2B depicts the reverse phase chromatograms in comparison to 
control (non-degraded) PS80. Chromatograms of intact PS80 had eight main peaks, with the 
most abundant species in each peak eluting in the order of POE sorbitan linoleic acid, POE 
sorbitan oleic acid, POE oleic acid, POE sorbitan linolenic/oleic acid, POE sorbitan 
linoleic/oleic acid, POE sorbitan i-oleic acid, POE sorbitan stearic/oleic acid and POE sorbitan 
trioleic acid. All eight main peaks correspond to sorbitan head groups except the POE-FA peak 
which has no head group attached. Isosorbide species eluted in the same order about one minute 
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before the equivalently substituted sorbitan species but were much smaller in peak area.  The 
average length of the POE chains was ~26 in the control PS80. This did not vary significantly 
between species of substituted head group, however the POE chain lengths in POE-FA were 
much shorter at about 10 POE units.  
After exposure to the esterase, PS80 shows a nearly complete loss of mono-substituted 
(sorbitan and isosorbide) and POE-FA species (Figure 3.2A). This is similar to a previous study11 
demonstrating that CALB preferentially degrades monosubstituted species. The di- and 
trisubstituted species remain almost completely intact. This enzyme did not show a preference 
between sorbitan and isosorbide head groups, degrading both impartially (data not shown). The 
primary degradation products following this reaction are free fatty acids (FFAs), POE-sorbitan, 
POE-isosorbides and n-POE groups (Figure 3.1, main hydrolysis products).  
After exposure to AAPH, PS80 exhibited partial loss of all quantified species. The more 
double bonds on the PS80 FA chain resulted in increased loss, consistent with previous results14. 
The di-substituted PS80 species in Figure 3.2A substituted with oleic acid at one position and 
stearic, oleic, linoleic, or linolenic, (18 : 0, 18 : 1, 18 : 2, 18 : 3 – carbons : double bonds) at the 
other show a downward trend of the fraction remaining. As the number of substitutions on the 
oleic acids on sorbitan head groups increase from 1 to 3, the loss increases from 74 to 48 to 38% 
remaining. Oxidation of PS80 produces an extensive variety of products (Figure 3.1) originating 
from the oxidation of either double bonds or allylic and bisallylic methylene groups present on 
the fatty acids (e.g. oleic acid, lineoleic acid) or oxidation of the POE chains. The peak which 
forms at 17 minutes (Figure 3.2) corresponds to di-oleic sorbitan POE with a hydroperoxyl 
addition (+32) similar to the product upper right corner of Figure 3.1. A shift to a smaller 
average number of POE units was also observed, resulting from oxidative cleavage of POE 
chains. 
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3.3.2 Langmuir Trough 
 To determine how degradation affected the interfacial properties of PS80, a Langmuir 
trough was used to measure surface pressure isotherms. Figure 3.3a shows the adsorption 
isotherms (surface pressure vs. time) of the degraded and non-degraded PS80 solutions without 
the mAbs. Compared to histidine buffer alone, all PS80 solutions show significant surface 
activity. Interestingly, the hydrolyzed species show a slower rate of adsorption, and a lower 
maximum surface pressure, compared to the non-degraded PS80. On the other hand, the 
oxidized PS80 shows an increase in the maximum surface pressure. Figure 3.3b shows the 
adsorption isotherms in the presence of the mAb solutions. mAb F in the absence of PS80 had a 
slow increasing adsorption rate (Figure 3.3b). The mixtures of mAb F and PS80 had a higher 
surface affinity than mAb F alone, since the polysorbate can diffuse to the surface and absorb 
competitively with mAb F. For a mixture of oxidized PS80 and mAb F, the initial rate of sample 
adsorption was similar compared to mAb F and PS80 control. Oxidized PS80 had the 
equilibrium highest surface pressure compared to control and hydrolyzed PS80 whether mAb F 
was present or not. The initial rate of adsorption for the hydrolyzed PS80/mab F mixture was 
the slowest of all three samples decreasing from 2.95 nM m–1 min–1 for control PS80 to 1.76 nM 
m–1 min–1 for hydrolyzed PS80. This suggests that the diffusion to the surface for the hydrolyzed 
PS80/mab F mixture is significantly slower than that of control PS80/mAb F mixture. Both 
samples had similar equilibrium surface pressures suggesting the affinity for the air/water 
interface remained unchanged. The critical micelle concentration (CMC) for each control and 
degraded PS80 was measured (Table 3.1) and significant difference were not detected between 
samples. 
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3.3.3 Shaking Stress 
 Accelerated degradation of mAb F/PS80 mixtures was performed to probe the ability of 
degraded PS80 to act as a surfactant and prevent the interfacial aggregation of mAb F. HPLC-
SEC was used to monitor the soluble fraction of antibodies and quantify soluble aggregates as 
well as the total monomer mass. During the shaking stress, mAb F lost 10% of the monomer 
fraction after one day and continued to lose monomer up to one week (Figure 3.4). A 
concentration of just 0.0001% control PS80 demonstrated protective effects, with the monomer 
fraction remaining intact after one full day. At concentrations of 0.01% and 0.001% PS80, a 
completely protective effect was provided against aggregation even for up to one week of shaking. 
Conversely, formulation with hydrolyzed PS80 resulted in a staggering loss of monomer at all 
concentrations. The monomer peak areas began to decline for all three concentrations of PS80 
samples after just one day of shaking. Formulation with oxidized PS80 resulted in a monomer 
loss profile that looks similar to the one for control PS80, with the 0.0001% solution resulting in a 
significant loss of monomer. All of the samples on SEC remained at a constant monomer peak 
fraction of ~97.5% monomer (Figure 3.S1).  
Aggregate particles were further quantified with MFI. For mAb F in the absence of 
polysorbate, a small number of particles (~3000) began forming after 2 h of shaking and reached 
a maximum number of particles after a day. For 0.0001% PS80, particles began forming after 8 
h, although the total number of particles at day one was much less than solutions without PS80 
(Figure 3.5). Similarly, hydrolyzed and oxidized PS80 showed particle formation after one day 
for 0.0001% PS80 containing solutions. For 0.001% and 0.01% PS80, both control PS80 and 
oxidized PS80 were protective against particle formation. However for hydrolyzed PS80, both 
0.001% and 0.01% resulted in a large number of particles with 0.01% having the highest of all 
conditions after one week. The distribution of particles at early time points for no PS80 and 
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0.001% PS80 containing samples are shown as a heat map in Figure 3.6. The samples containing 
0.001% hydrolyzed PS80 had the highest number of particles >25 um after 2 hr. The samples 
containing the PS80 control and oxidized PS80 had similar particle distributions in regard to size 
and aspect ratio. 
Visual inspection was performed at all time points and vials after one week of shaking are 
pictured in Figure 3.7. At later time points (3 days, 1 week), particles in some samples began to 
stick to the vial. The morphology of the particles in solution also appears different between the 
different vials. Esterase degraded samples resulted in an opaque coating of samples on the surface 
of the vial, while mAb F shaken without PS80 resulted in a smaller snowflake like coating of 
particles. The 0.0001% oxidized polysorbate resulted in larger particles adsorbed to the surface 
of the vial.  
3.4 Discussion 
We have compared the two most common degradation mechanisms for polysorbate 80, 
oxidation and enzymatic hydrolysis, and their downstream effects on surfactant properties and 
protein aggregation. Mass spectrometry was used to quantify the degradation of the individual 
species of polysorbates. The CALB enzyme used here selectively cleaved monosubstituted PS80 
species nearly completely. Use of immobilized enzymes allowed creation of a degraded PS80 that 
can be easily separated from the lipase and used for further experimentation. Similarly, the use of 
light and AAPH was effective for producing oxidized samples which could be stored for later use 
since all of the AAPH is reacted. Photolysis of AAPH results in the creation of the peroxyl 
radicals though the following proposed mechanism17:  
which in the presence of oxygen can convert to peroxyl radicals  and 
subsequently . The peroxyl radicals generated showed preference for PS80 
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species with more double bond substitutions. Oxidized PS80 ranged from 10% to 70% intact 
(not degraded) depending on the species. 
 The rate at which PS80 diffuses to the air/water interface may be critical for prevention 
of antibody aggregation during shaking stress as PS80 is constantly being displaced and has to 
compete for interfacial surface area with proteins. The initial rate of change of surface pressure 
has been shown to predict the aggregation rates for a panel of antibodies18. For the samples 
described here, the degraded PS80/mAb F mixtures adsorbed had slower initial adsorption rates 
than control PS80, with hydrolyzed PS80 adsorbing the slowest. The decrease in initial rate of 
change in surface pressure could indicate hydrolyzed PS80 becomes less competitive with mAb F 
at the air/water interface, leading to higher mAb F interfacial concentrations which result in 
crowding and aggregation. Oxidized PS80 and control PS80 both had higher initial rates of 
change of surface pressure and were both effective at preventing mechanical aggregation. While 
differences were observed using the Langmuir trough, the CMC remained unchanged between 
intact and degraded PS80 as measured using pyrene (Table 3.1). Further, no differences were 
observed in the melting temperature of mAb F in the presence of control or degraded PS80 (data 
not shown). This suggests that differences between samples is not due to specific interaction of 
PS80 and mAb F.  
 For shaking stress, monomer loss rates were fastest for mAb F in the absence of PS80 and 
mAb F mixed with hydrolyzed PS80. Even at the highest concentration of 0.01%, hydrolyzed 
PS80 was unable to protect against monomer loss. The concentration of intact PS80 is 0.006% 
with 0.004% of polysorbate having been hydrolyzed. The concentration of intact PS80 should 
still be high enough to prevent protein aggregation as control PS80 at 0.001% was still effective 
at preventing monomer loss. This indicates that the hydrolyzed PS80 products are catalyzing 
protein aggregation. For all samples, the SEC soluble percent of dimer or higher molecular 
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weight species percent did not increase during shaking (Figure 3.S1). This suggests that 
aggregation is occurring at the interface2,19.  
 After just 2 h of shaking the hydrolyzed PS80 with mAb F, there is a larger number of 
particles over 25 μm than any of the other samples (Figure 3.6, top panel). The hydrolyzed 
polysorbate 80 resulted in particles with a morphology distinct from that of particles generated by 
samples of mAb F without PS80. The hydrophobic nature and low solubility of free fatty acids 
are responsible for creation of particles of this type20. We hypothesize these particles acted as 
nuclei which accelerated further protein aggregation and precipitation. The average aspect ratio 
for particles generated after 24 h (Figure 3.6, lower panels) of shaking in the presence of 
hydrolyzed PS80 was closer to 0.6 while for mAb without PS it was ~ 0.35. Further, the size 
range of the particles generated in the presence of hydrolyzed PS80 was wider, many particles 
bigger than 50 μm were observed.  
 The loss in the total number of particles observed by MFI (Figure 3.5, No PS80) can be 
explained both by a shift to larger average particle size as well as by the sticking of particles to the 
interior surface of the glass vials. For hydrolyzed PS80, both 0.0001% and 0.001% solutions 
resulted in particles sticking to the vial while 0.01% remained in solution (Figure 3.7). This 
corresponds well with the total particles measured per mL, where both 0.001% and 0.0001% see 
a drop in particle counts at three days and one week, while 0.01% continues to increase. This 
concentration dependence could stem from the low concentrations of PS80 inability to coat the 
surface of the vial. It is also possible that higher levels of intact PS80 can keep protein and/or 
fatty acid aggregates in solution as opposed to adsorbed on glass surfaces. While at 0.01% there is 
enough PS80 to prevent adsorption to the vial but aggregation still occurs. It is important to note 
that both MFI and SEC are unable to quantitate particles adsorbed to the surface of vails. 
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There has been considerable interest in designing improved surfactants as alternatives to 
polysorbate for protein stabilization21,22. While novel surfactants may be more effective than 
polysorbate at preventing degradation, designing a surfactant with resistance to many types of 
degradation will be critical. PS80 has been available in increasingly purified formulations 
recently and the Chinese Pharmacopeia changed its requirements form <58% oleic acid to 
<99% oleic acid as well as decreasing tolerances for peroxides. Linoleic and linolenic fatty acids 
are more susceptible to oxidative degradation than oleic acid. Therefore we anticipate that 
reduction in levels of linoleic and linolenic fatty acids will result in PS80 more robust to oxidative 
stress.  
In this study, we found hydrolysis of PS80 to be more problematic for antibody 
formulations than PS80 oxidation. Therefore, monitoring and hindering the enzymatic 
hydrolysis of PS80 is critical for preventing aggregation. Methods to monitor levels of free fatty 
acids impurities can be used to compare different product purification steps or formulation 
conditions23. Specific enzymes which hydrolyze PS80 can be identified using proteomics 
approaches and knocked-out of a cell-line if necessary9,12.  
3.5 Conclusion 
 Polysorbate 80 is the most common excipient in protein formulation for its ability to 
prevent protein interfacial aggregation. To compare the effects of polysorbate oxidation and 
enzymatic hydrolysis, we used forced degradation. LC-MS was used to quantify the loss of 
individual components which make up PS80. Adsorption isotherms of PS80/mAb F mixtures 
were produced using Langmuir trough to investigate differences in surface activity of equivalent 
systems to those investigated with mechanical agitation. PS80 and PS80/mAb F mixtures 
degraded by hydrolysis had slower adsorption rates compared to control or oxidized PS80 and 
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PS80/mab F mixtures, respectively. Degraded PS80/mAbF solutions showed an increase in the 
equilibrium surface pressure, when the degraded through oxidation. During mechanical agitation 
studies of mAb F in the presence of PS80, control polysorbate was able to prevent aggregation at 
concentrations as low as 0.001%. After subjecting PS80 to ~40% hydrolysis a concentration of 
0.01% PS80 could not protect against monomer loss, even though the concentration of intact 
PS80 remaining (0.006%) was higher than protective controls. Oxidized PS80 was similarly 
protective to control PS80, despite ~40% of PS80 being oxidized. During hydrolysis of PS80 the 
sole products are free fatty acids, while PS80 oxidation has several degradation pathways, with 
free fatty acids being a minor product. Hydrolyzed PS80 both generated more particles and had 
a slower initial rate of change in surface pressure compared to control and oxidized PS80. Since 
hydrolyzed PS80 has a slower initial rate of surface pressure change, higher concentrations mAb 
F can absorb to the interface and result in faster interfacial aggregation. The generation of 
insoluble hydrophobic particles from free fatty acids may accelerate protein monomer loss by 
acting as nucleation sites for protein aggregation. These effects could be synergistic, with both 
higher concentrations of mAb F at the interface and more interfacial nucleation sites at 
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3.7 Figures and Tables 
 
Figure 3.1. Reaction scheme for PS80 degradation, POE(n) sorbitan oleate is shown as it makes 
up the largest percentage of PS80. The oxidative pathway can proceed through a radical adjacent to the 
double bond. This pathway leads to n- POE (n)The radical can also form on the carbons in the POE 




Figure 3.2. A) Fraction of PS80 species intact after forced degradation. Species depicted are POE 
sorbitan substituted except for POE-FA which is just POE oleic acid. The number of POE units in all 
cases is 26 except for POE-FA there are 10 POE units. Error bars represent the standard deviation of 
three replicates. B) Reverse phase chromatograms for PS80. Brackets denote the number of fatty acid 
substitutions on the head group (sorbitan, isosorbide).  Top: Chromatograms for stock PS80 and 
hydrolyzed PS80. Bottom: Chromatograms for stock PS80 and oxidized PS80. Error bars represent the 
standard deviation of three replicates. *Oleic acid listed twice, the first oleic acid species corresponds to 
monosubstituted sorbitan oleic acid while second species corresponds to polyethylene-oxide oleic acid. 
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Figure 3.3. A. Surface pressure vs. time for stock and degraded PS80 solutions, as well as the 
histidine buffer without PS80. The graphs represent the average of two replicates.  B. Surface pressure 






















Figure 3.4. Monomer area peak fraction for the various polysorbate 80 time points. Peak areas are 




Figure 3.5. Particle counts for shaken samples at various timepoints for the different degraded 
polysorbates. Particle counted are in the size range of 2 – 100 μm. Error bars represent the standard 




Figure 3.6. Particle morphology heat maps for the 2 h, 8 h and 24 h timepoints of the shaking 
study. The PS80 concentration in these samples was 0.001% (wt/v). Points on the plot represent 
individual measured particles. The color of each point is scaled by a 2d histogram binning of the number 





Figure 3.7. Picture of vials of mAb F after one week of shaking with various polysorbate 





Figure 3.S1. Change of SEC determined monomer percent over time for mAb F formulated with 






Figure 3.S2. Ratio of fluorescence pyrene peaks at 373 nm to 384 nm (l1/l3) used to determine the 
CMC for PS80 and its degradants. 
  
















Figure 3.S3. Particle morphology heat maps for the 2 h, 8 h and 24 h timepoints of the shaking 
study. The PS80 concentration in these samples was 0.001% (wt/v). Points on the plot represent 
individual measured particles. The color of each point is scaled by a 2d histogram binning of the number 





4 Conformational Changes and Drivers of Monoclonal 
Antibody Liquid-Liquid Phase Separation  
4.1 Introduction 
Protein liquid-liquid phase separation (LLPS) occurs when a solution can achieve a lower 
energy state by partitioning itself into two phases1. An equilibrium is reached when the chemical 
potential is equal in the two phases. Thus, phase transitions occur about critical points of solution 
chemical potential. One phase is dense, viscous and protein-rich while the other phase is protein-
poor2–4. Entropic and enthalpic effects can both promote LLPS. It is possible for non-interacting 
particles to exhibit phase separation solely via entropic effects (i.e. osmotic depletion)5. Most 
proteins, however, do not exhibit phase separation even at high protein volume fractions2–4. 
Therefore protein-specific interactions primarily dictate whether a protein will undergo phase 
separation and the shape of the liquid-liquid coexistence curve. Ionic, hydrophobic, pi-pi, van 
der Waals, hydrogen bonding, and other forces can all contribute to favorable protein-self 
interactions which drive LLPS4.  
Weak self-associative interactions at high volume fractions cause proteins in solution to 
form transient clusters6. In the case of phase separation, these clusters form larger branched 
networks of proteins which make up the protein-rich phase7. Neutron spin echo and small-angle 
neutron scattering experiments have identified the formation of dynamic clusters of proteins 
(including antibodies) in concentrated solutions8–10. Increases in solution viscosity are a result of 
higher average protein cluster size in solution6,11. For monoclonal antibody solutions, increases in 
viscosity are particularly problematic at high concentrations (>100 mg/ml), and many 
pharmaceutical formulation approaches have been developed to mitigate high solution 
viscosities12,13.  
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LLPS also plays a critical role in compartmentalization within cells4,14. Accurate 
characterization of protein phase separated components in cells is performed primarily using 
imaging approaches. The use of many conventional biophysical tools for structurally 
characterizing proteins (e.g., CD, temperature melts, UV-Vis absorbance, etc.) is severely limited 
at such high protein concentrations. As LLPS is a thermodynamically reversible phenomenon, 
dilution of phases to lower protein concentrations results in solutions with equivalent physical 
properties (a single phase). Therefore physical characterization of LLPS cannot be performed by 
diluting the protein-rich and protein-poor phases to concentrations suitable for experimental 
characterization.  
Here, we use a variety of spectroscopic techniques capable of characterizing protein phase 
separated components without dilution thereby preserving their actual physical state and 
allowing the study of protein conformational integrity in each phase. Protein structural 
differences between the protein-rich and protein-poor phases were measured using Raman, 
fluorescence and FTIR spectroscopy. Several spectroscopic observables undergo consistent shifts 
for all three antibody proteins in the individual phases. FTIR was also used to investigate the 
dynamics of water in the protein rich and protein poor phases. We determined specific sequences 
participating in protein-self interactions using hydrogen-deuterium exchange (HX-MS). Finally, 
we compared the aggregation rates for the three antibodies in the protein-rich and protein-poor 
phases and observed greater aggregation rates in the protein-poor phase for two of the antibodies 
and equivalent aggregation rates in two phases for the third antibody. 
4.2 Materials and Methods 
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4.2.1 Materials and sample preparation 
One IgG4 (mAb Z) and two IgG1 (mAbs H and I) monoclonal antibody stock solutions 
were provided by MedImmune LLC. These proteins were extensively dialyzed against buffers 
(Table 4.1) in which they could undergo LLPS at room temperature (room temperature, RT, ~ 
22 °C) using dialysis cassettes (Slide-A-Lyzer™, 10 kDa MW cutoff, ThermoFisher Scientific, 
Waltham, MA). The individual phases could not be isolated directly from the dialysis cassettes 
due to high viscosity. The two resultant phases of each mAb were first mixed inside dialysis 
cassettes, then the mixture was transferred to a Falcon tube and kept still overnight at RT until 
two phases again formed with a clear boundary. Samples of each phase were obtained by 
decanting the protein-poor phase into a separate falcon tube. The pH and protein concentrations 
of the two phases (protein-poor and protein-rich) were measured using a pH meter and a 
Nanodrop spectrometer (Thermo Scientific), respectively (Table 4.1). These two phases of each 
mAb were later subjected to biophysical and analytical analyses. 
To investigate the temperature effect on the LLPS of these mAbs, freshly dialyzed samples 
were stored in Eppendorf tubes at 25, 22, 15, and 4 °C. Concentrations of the newly formed 
protein-poor phases were measured every 24 h until they remained unchanged, indicative of 
thermodynamic equilibrium of LLPS. Upon equilibrium, concentrations of the protein-rich 
phases were measured using a Nanodrop spectrometer (Thermo Scientific) to construct liquid-
liquid coexistence curves. 
The liquid-liquid coexistence curves derived from mean field theory were fit as described15 
to: 
|(C( 	− 	C)/C(| = A[(T( − T)/T(]) 
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Where Cc is the critical protein concentration, Tc is the critical temperature in degrees 
Kelvin, A parameterizes the width of the coexistence curve, and β is the Ising exponent (0.325). 
The standard error of the mean on the fitted parameters was calculated as described16. 
4.2.2 Quantification of spectroscopic peaks 
Spectroscopic peaks from Raman, fluorescence and FTIR were quantified using a variety 
of methods. The first three central moments of a peak were used to quantify peaks. 
The zeroth moment is equivalent to the total peak area or total intensity: 
I*+* =	F I(λ)dλ 










The full width at half peak max (FWHM) for a Gaussian peak shape is the peak’s standard 
deviation 𝜆- multiplied by a factor: 
𝐹𝑊𝐻𝑀 = 	2.355 ∗ 𝜆- 	
The peak maximum λmax was also used by interpolating between points using a cubic beta 
spline interpolation to 0.01 cm–1 for determining the wavelength maximum of the amide I band 
by FTIR. Ratios of peak intensities of two wavelengths are donated as Ix/y, with x and y denoting 
the two wavelengths at which the ratio of intensities was taken. 
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4.2.3 Raman Spectroscopy 
Raman spectra of protein samples were collected using a Zetasizer Helix (Malvern 
Instruments, Columbia, MD) equipped with a 785-nm laser (~280 mW). Protein samples (20 μL) 
were loaded into a metal micro-cuvette (Malvern) assembled with two quartz windows. For 
protein concentrations and buffers for each mAb, see Table 4.1. Samples were measured using 
10 acquisitions of 20 sec each. Raw spectra were processed and analyzed using the Zetasizer 
Helix Analyze software (Malvern Instruments). Raman spectra were first buffer subtracted and 
normalized according to the phenylalanine peak (1003 cm–1). The amide I band first moment 
and FWHM were calculated from 1630 – 1690 cm–1. 
4.2.4 FTIR Spectroscopy 
FTIR analysis was performed using a Tensor-27 FTIR spectrometer (Bruker, Billerica, 
MA). For protein concentrations and buffers for each mAb, see Table 4.1. Protein samples were 
measured from 800 – 4000 cm–1 with a resolution of 4 cm–1. A total of 256 scans were performed 
for both samples and buffers at 25 °C. For the thermal melting experiments, 64 scans were 
obtained and samples were scanned from 25 to 90 °C using an increment of 2.5 °C/step and an 
equilibration time of 2 min at each step. Buffer subtraction, water vapor and CO2 compensation, 
baseline correction, and normalization of amide I band (1700 – 1600 cm–1) were sequentially 
performed on the raw FTIR spectra using the OPUS V6.5 software (Bruker, Billerica, MA). 
Second derivative FTIR spectra were generated using a Savitzky–Golay filter with a window size 
of 9.  
The bend + liberation FTIR band of water in these protein samples and their buffers were 
measured by using air as the blank. Samples were scanned from 800 to 4000 cm–1 using a 
	 102 
resolution of 2 cm–1. A total of 256 scans were performed. λμ was calculated between 1900 and 
2300 cm–1 for the water band. 
4.2.5 Intrinsic Fluorescence Spectroscopy 
Intrinsic fluorescence spectra were obtained using a fluorescence plate reader as previously 
described17,18. Samples were loaded into a 384-well plate and silicone oil was added to avoid 
sample evaporation during thermal ramps. The plate was centrifuged at 2,200 × g for 1 min to 
remove air bubbles. For protein concentrations and buffers for each mAb, see Table 4.1. 
Samples were excited at 295 nm (>95% tryptophan emission) using an acquisition time of 100 
ms, and emission light from 300 to 450 nm were collected. Temperature was ramped from 10 to 
100 °C with an increment of 1 °C per step and an equilibration time of 2 min at each step. The 
mean fluorescence emission wavelength, λμ, was calculated between 300 and 400 nm. The λμ 
provides a better signal-to-noise ratio than the actual peak position (i.e. maximal point), although 
it is often 5 to 10 nm higher than the latter one due to the asymmetry of protein intrinsic 
fluorescence spectra. The integral of fluorescence spectra between 300 and 400 nm was taken as 
total fluorescence intensity (Itot). Both parameters (λμ and Itot) were plotted as a function of 
temperature to construct the melting curves. Their first derivative curves were generated using a 
Savizky-Golay smoothing function with a polynomial order of 2 and window size of 11 built by 
employing the Origin software (OriginLab Corporation, Northampton, MA). The local 
maximum was taken as the melting temperature. 
4.2.6 Differential Scanning Calorimetry (DSC)  
The overall conformational stability of proteins was investigated using a VP-Capillary 
micro-calorimeter (Malvern, UK). The buffers for each mAb are listed in Table 4.1. The three 
mAb samples (at 1 mg/mL) in their corresponding dialysis buffers were loaded into a 96-well 
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plate kept in a 5 °C sample chamber. Samples was scanned from 10 to 100 °C with a ramp rate 
of 2 °C per min. Samples were pre-equilibrated for 15 min prior to each scan. Raw DSC 
thermograms were buffer subtracted, normalized for concentration, and baseline corrected using 
the DSC Origin software (OriginLab Corporation, Northampton, MA). 
4.2.7 Static light scattering  
 Static light scattering was obtained using a fluorescence spectrometer (Photon 
Technology International, Birmingham, NJ) equipped with a xenon arc lamp, excitation and 
emission monochromators, and a temperature controllable 4-position cuvette holder. For protein 
concentrations and buffers for each mAb, see Table 4.1. Light at 450 nm was scattered at 90° 
detection angle with an acquisition time of 1 sec. Temperature was ramped from 25 to 100 °C 
using an increment of 1 °C per step and an equilibration time of 120 s.  
4.2.8 Lyophilization of mAb H and mAb I Samples 
Both mAb H and mAb I were lyophilized for use in HX-MS spectrometry studies. Samples 
of proteins at 5 mg/ml and 60 mg/ml were dialyzed against 40 mM phosphate and 10% 
trehalose at pH 7.5. A LyoStar II (SP Scientific, Warminster, PA) was employed to lyophilize the 
samples as described previously19–21. Lyophilized cakes were photographed. Reconstituted 
samples were passed through a 0.22 um filter and the absorbance at 280 nm was used to quantify 
the sample concentrations.  
4.2.9 Karl-Fischer Titration 
Water moisture levels of lyophilized mAb samples was determined using a C20 Compact 
Karl-Fischer Coulometer (Mettler-Toledo LLC., Columbus) though measurement of their 
reaction with AQUASTAR ® CombiCoulomat (EMD Chemicals Inc., Gibbstown, NJ). Weights 
of lyophilized cakes were used to calculate their water moisture content. 
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4.2.10 Hydrogen-Deuterium Exchange Mass Spectrometry 
HX-MS was performed for both mAb H and mAb I as described perviously19. Lyophilized 
vials containing 5 and 60 mg/ml protein in 40 mM phosphate with 10% trehalose at pH 7.5 
were equilibrated at 25 °C. Samples were reconstituted in an equivalent deuterium buffer for 
labeling times of 120, 103, 104, and 105 s. A quench buffer of 0.5 M tris (2-carboxyethyl) 
phosphine hydrochloride (TCEP), 4 M guanidine hydrochloride and 0.2 M sodium phosphate at 
1 °C was used to halt deuteration by diluting 20 μL of the sample with 180 μl of quench buffer. 
Quenched samples were loaded into the sample loop using a LEAP H/DX PAL (LEAP 
Technologies, Carrboro, NC). The LC (Agilent 1200 series, Santa Clara, CA) consisted of an 
immobilized pepsin column, peptide desalting trap, and a C18 column. The total mass of sample 
injection was kept constant by modifying the injection volume. Three independent replicates 
were measured using a quadrupole-time-of-flight mass spectrometer (Agilent 6530, Santa Clara, 
CA) with an electrospray ionization source in positive mode. Complete deuterium uptake plots 
for all timepoints and concentrations are included in the supplemental information as PDFs, 
black circles represent the 5 mg/ml concentration and red triangles represent the 60 mg/ml 
concentration. 
4.2.11 Homology Modelling 
Homology models were constructed using by modeling. Homology models of the Fab 
domain of each antibody were generated using the Antibody Modeler within MOE22, a 
computational modeling package from CCG. Templates were identified using X-ray structures 
of the most homologous antibodies from more than 4,000 antibody structures in the Protein Data 
Bank (PDB).  
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4.2.12 Protein aggregation in Two Phases by Size Exclusion Chromatography (SEC) 
 Samples were held at 40 °C in the instrument autosampler for a two-week stability study. 
For protein concentrations and buffers for each mAb, see Table 4.1. The protein-poor and 
protein-rich phases were separated using positive displacement pipettes and placed in HPLC 
vials with insets (150 μL total volume). To prevent sample evaporation, a small amount (15 μL) of 
silicone oil was overlaid on the sample. Injections were performed without diluting the sample. 
For the protein-rich phase, 0.2 μL of sample was injected onto the column. For the protein-poor 
phase, the amount injected was different for each antibody but determined so that the total 
protein mass of the injection was equivalent to the protein-rich phase. This was done by 
multiplying 0.2 μL by the concentration ratio of the protein-rich and protein-poor phases. 
SEC was performed employing an HPLC instrument (Shimadzu, Kyoto, Japan) equipped 
with an autosampler, a column oven, and a UV detector. Samples were injected on a TSKgel 
SWXL guard column (6.0 mm x 40 mm) followed by a TSKgel G3000SWXL SEC column 
(7.8mm x 300 mm) at a flow rate of 0.7 mL/min for a total run time of 30 min. The mobile 
phase used was 0.2 M sodium phosphate, pH 6.8, and the column oven was set at 30 °C. SEC 
chromatograms were detected at 280. Total peak areas remained approximately constant 
through-out the stability study and protein recovery was near one hundred percent. 
 
4.3 Results 
4.3.1 LLPS of Three Different mAbs  
The three mAb samples had previously been observed to undergo LLPS in low ionic 
strength solutions at pH values near their pI. We extensively dialyzed each of these three proteins 
against specific buffers in which LLPS occurred at room temperature as described in Table 4.1. 
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High concentrations of proteins are known to exhibit the Gibbs-Donnan effect during dialysis 
due to preferential retention of oppositely charged ions by charged protein molecules resulting in 
an offset in solution conditions (pH and ion concentrations) between dialysis buffers and dialyzed 
samples23. Therefore we measured the pH of the dialyzed mAb samples to evaluate the 
magnitude of the Gibbs-Donnan effect during dialysis. Both protein-rich and protein-poor phases 
of each mAb were found to have pH values close to the pH of their dialysis buffers (±0.04), 
suggesting complete dialysis and an insignificant Gibbs-Donnan effect (Error! Reference s
ource not found.). This may be attributed to the net neutral charge of mAbs in their dialysis 
buffers with pH values close to their pI. It therefore seems reasonable to assume a similar buffer 
composition in the two phases for each of these three mAbs. 
4.3.2 Temperature-Dependent LLPS of Three mAb Proteins  
The LLPS of proteins is a temperature-dependent thermodynamic equilibrium process24,25. 
Temperature dictates solution entropy contributions and the magnitude of protein-protein 
interactions (PPIs), which are important driving forces for the formation of LLPS. We 
investigated how temperature affects the LLPS of these three mAbs in specific buffers (Table 4.1) 
by constructing their liquid-liquid coexistence curves with the x and y axis representing protein 
concentration and temperature, respectively. Most proteins show a concave-down profile26. 
Above the coexistence curve, proteins are thermodynamically stable as a homogenous solution. 
Beneath this curve, protein solutions form two phases with distinct concentrations (specified by 
the liquid-liquid coexistence curve) under equilibrium conditions. LLPS was induced for each of 
the three mAbs at 4, 15, 22 and 25 °C, and the protein concentrations of the rich and poor 
phases were measured upon equilibrium. Figure 4.1 depicts how increasing temperature resulted 
in an increase and decrease in concentrations of the protein-poor and rich phase, respectively.  
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Out of these three proteins in their respective buffers, mAb Z and I had low Tc while mAb 
H had the highest. Full parameters of the fit to mean field theory equations are provided in Table 
4.2. The three antibodies studied here have similar critical volume concentrations near 125 
mg/ml. The small critical volume fraction of antibodies is presumably a consequence of network 
formation at high concentrations9,27. Antibodies are homodimers; if any region of the Fab 
(antigen binding fragment) is involved in protein self-association there are two binding sites per 
protein. Since an antibody molecule has two binding sites, if two antibodies bind in the Fab 
region then the resulting dimer also has two unoccupied binding sites. This association behavior 
permits formation of infinitely long chains of antibody molecules. 
4.3.3 Structural Comparisons of the Three mAb Proteins in the Two Phases 
Next, we address whether three different mAb proteins in these two phases share identical 
structural properties. The overall secondary and tertiary structures of mAb proteins in the two 
phases were analyzed and compared using multiple biophysical techniques. Since these samples 
are highly concentrated (> 200 mg/mL for protein-rich phases), the use of several commonly 
employed spectroscopic techniques is limited. Techniques specifically suitable to examine 
structural properties of these highly concentrated samples were therefore used. 
4.3.4 Raman spectroscopy  
Raman spectroscopy was able to detect differences in protein secondary and tertiary 
structure between the protein-rich and protein-poor phases. Overall, however, the normalized 
protein spectra of the top and bottom phases were highly similar (Figure 4.S1). The largest 
dissimilarities were observed in the spectral region of disulfide bands (Figure 4.2). IgG1 and IgG4 
antibodies both have twelve intrachain and four interchain disulfide bonds28. The SS stretching 
vibrations of disulfides in a protein provide specific information about the geometry of the 
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dihedral angles. A disulfide bond has two CS bonds adjacent to the SS bond. The CSSC 
dihedral angle is typically gauche (G), with angles near 90° or –90°. The CS bonds adjacent to 
the SS bond usually take a gauche (G) or trans (T) conformation. Raman spectra can distinguish 
between GGG, GGT, and TGT conformations of the CS, SS, and SC bonds in disulfides. GGG 
conformers have a vibrational stretching frequency near 510 cm–1, and the trans conformations 
in CS bonds adds roughly 15 cm–1 of bond strain. Therefore, GGT conformations have a 
stretching frequency of approximately 525 cm–1 while TGT have a stretching frequency near 540 
cm–1. These three peaks are present in the spectra shown in Figure 4.2 for all three antibodies.  
We then compared the relative intensities of the TGT and GGG bands using the ratio of 
their intensities (I540/510). For the protein-rich phase of mAbs I and H, the ratio of GGG to TGT 
conformers is half that of the protein-poor phase (Table 4.3). For mAb Z, the GGG peak is 
nearly absent in the protein-poor phase resulting in a I540/510 ratio of 7.4. The changes in disulfide 
structures may be isotype specific since interchain disulfides in the Fab domain are distinct in 
IgG1 and IgG4. A peak at 490 cm–1 is present in all three protein-rich phases but missing in the 
spectra of mAb H and I protein-poor phases. A disulfide stretching vibration of 490 cm–1 can 
originate from dihedral angles of about 25°29. The absence of this band in the protein-poor IgG1 
phases again suggests a significantly altered state of disulfide bonds in the protein-rich phases of 
IgG1 molecules. It is expected that the bond energies would be much higher for disulfide bonds 
with SS angles at 25°. The hinge regions of antibodies have long been recognized for their 
intrinsic flexibility30. Disulfide bonds covalently stabilize the Ig domains of antibodies. The 
additional strain in these regions suggests that domain positional adjustments may be necessary 
to form protein networks in solutions of antibodies. 
The tyrosine ratio of the Fermi doublet (I855/830) was used to quantify the hydrogen bond 
donor and acceptor preference of tyrosine in the two phases31. For all three proteins the I855/830 
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was lower in the protein rich phase (Table 4.3) signifying a shift to tyrosine as a stronger 
hydrogen bond donor. This effect was most pronounced for mAb H with a shift from 1.77 to 
1.57. The amide I band λmax at 1670 cm–1 indicates the antibodies are primarily beta sheet 
structure as expected. The amide I band moment exhibited a blue-shift of ~1 cm–1 for all three 
antibodies in the protein-rich phase compared to the protein-poor phase (Table 4.3). Band 
narrowing was also observed for the protein-rich phase as well; the FWHM of the amide I band 
decreased by 1 – 2 cm–1. Band narrowing of the amide I band could be the result of restriction of 
the number of accessible conformational states in the protein-rich phase.  
4.3.5 FTIR Water Band 
 Antibodies in the protein-rich phase are thought to form extensive interaction networks in 
an aqueous environment. The volume fraction of mAbs at 250 mg/mL is 17.8% when calculated 
with a specific volume of 0.71 mL/g for proteins2. We hypothesized such a large change in 
volume fraction could affect the structure and dynamics of solvent water. The bend + liberation 
(BL) FTIR band of water is a sensitive intrinsic probe of water dynamics and structure32. The 
position of the BL band can be used as a qualitative measure of the rigidity of water’s hydrogen 
bonding network. For example, high temperature weakens water’s hydrogen bonding and is 
accompanied by a red shift in the BL band position. A kosmotrope (a solute water structure 
maker) often causes a blue shift in the position of the BL band, suggesting a stronger water 
hydrogen bonding network. Conversely, a chaotrope (water structure breaker) induces a red shift. 
Protein-poor phases have equivalent band positions to their corresponding buffers (Figure 4.3). 
This suggests that water in low-ionic strength buffers and in the protein-poor phase has similar 
dynamic properties. A blue shift ( ~2 cm–1) of the BL band, however, was observed for the 
protein-rich phases compared to the poor phases, suggesting water in the protein-rich phase is 
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more structured. These measurements suggest that while water is only weakly involved in protein 
phase separation, it may be important in the development of more sophisticated theories for 
LLPS. Water molecules in the two phases have different dynamic properties but reach 
thermodynamic equilibrium. It may be interesting to study water dynamics or simulate water 
diffusion across the phase boundaries to better understand the LLPS of protein solutions. 
4.3.6 FTIR Amide I region 
The amide I FTIR band (between 1700 and 1600 cm–1) primarily derives from the 
stretching of the amide carbonyl group and therefore reflects the backbone pattern of hydrogen 
bonding of a polypeptide. Various secondary structure types show distinct amide I bands (e.g. 
alpha helix, intramolecular beta sheet, intermolecular beta sheet, beta turn, and random coil). 
The amide I band of the protein-rich phase red shifted by ~2 cm–1 relative to that of the more 
depleted phase for all three mAbs, indicative of subtle structural differences (Figure 4.4 and 
Figure 4.S2). The reversibility of these changes was further tested by comparing FTIR spectra of 
the more dilute and rich phases at a concentration equivalent to its corresponding depleted 
phase. They were found to share identical amide I spectra (data not shown), indicating structural 
changes seen in the protein-rich phase are reversible upon dilution. 
Protein-rich phases showed significantly more intermolecular β sheet (1614 cm–1) than the 
protein-poor phases (Figure 4.S2). A red shift of the stronger main peak is accompanied by an 
increase in intermolecular β sheet. The main peak maximum corresponds to primarily beta sheet 
structure. The beta sheet rich structures of antibodies participate in extensive intramolecular 
hydrogen bonds. This red shift in the amide I band is observed for all three proteins. The 
decrease in energy of the amide I band could arise from alterations in the beta sheet structure 
such as the sheet twist angle. The red shift could also result from small specific changes in 
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sidechain positions. It is also possible there are some stabilizing non-bonded interactions such as 
n → π* interactions of carbonyl lone pairs and carbonyl π* orbitals at the protein-protein 
interface which lower the energy of the amide I band33. While we are uncertain about the exact 
nature of the red shift, it is consistent across the three antibodies studied as also seen with the blue 
shift observed in tryptophan fluorescence (see below). The amide I red-shift in FTIR and blue-
shift in Raman may be opposite in direction because of the different selection rules for the two 
methods (dipole moment and polarizability changes for FTIR and Raman, respectively). 
FTIR peak position of spectra (Figure 4.4) was followed as a function of temperature 
(Figure 4.5). All three mAbs for both phases exhibited large red shifts upon aggregating to a peak 
at 1624 cm–1 (Figure 4.5). This peak has previously been assigned to amorphous aggregates of 
IgG1 antibodies following thermal unfolding and aggregation34. Spectra prior to the melting 
temperature do not exhibit significant change, indicating that the overall secondary structure 
differences between the proteins in the two phases are maintained until structural alterations and 
aggregation initiates. 
4.3.7 Intrinsic Tryptophan Fluorescence 
Tryptophan residues can be used as intrinsic fluorescent probes for protein structural 
changes since their fluorescence is sensitive to the polarity of their immediate environment. The 
protein-rich phases exhibited a blue-shifted λμ by 1 – 2 nm compared to their corresponding 
depleted phases at 25 °C, suggesting Trp residues are on average more buried in the protein-rich 
phase. Trp residues could either be buried because of tertiary structural changes or by their 
involvement in protein-protein interactions at interfaces. The blue-shifts seen are not artifacts 
due to inner filter effects since such an artifact usually results in a red-shifted emission35. The 
twelve indole sidechains in antibodies which participate in nonbonded interactions with 
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intrachain disulfides are designated Trp triads36. Conformational changes within the Trp triad 
could be responsible for the observed blue shift in Trp fluorescence that are accompanied by the 
changes in the disulfide dihedral angles seen with Raman spectroscopy.  
To further probe the spectral shift observed in the protein-rich phase, fluorescence was 
observed during thermal ramps from 25 to 90 °C (Figure 4.6A – C). The blue-shift of λμ for the 
protein-rich phase persisted prior to the thermal transitions for all three mAbs. Typical red shifts 
of λμ were observed upon melting, although the protein-rich phases (mAb Z, mAb H, and the 
second transition of mAb I) exhibited stronger thermal transitions than their corresponding 
protein-poor phases. The post-transition baselines of the two phases nearly overlapped for each 
mAb. This indicates a disruption of the underlying difference between the protein-rich and 
protein-poor phases upon thermal unfolding. 
Compared to λμ, total fluorescence intensity (Itot) correlates linearly with the degree of 
unfolding of a protein and therefore was used to generate Tm values (Table 4.S1)18. Similar to 
results in Figure 4.6, mAb Z showed only one transition, while the other two mAbs manifested 
two (Figure 4.S3A – C). Their first derivative plots also confirm the number of transitions 
(Supplemental Figure 4.S3D – F). First derivative plots of the protein-poor phase samples show 
thermal profiles consistent with DSC thermograms (Figure 4.6. Thermal stability of the proteins 
in the two liquid phases of the mAb samples measured by intrinsic tryptophan fluorescence 
spectroscopy. The mean fluorescence emission wavelength (λμ) of (A) mAb Z, (B) mAb H and (C) 
mAb I. See Table 4.1 for protein concentrations and solution conditions. (D) DSC thermograms 
for mAb Z, H and I (at 1 mg/ml).D), illustrating the ability of fluorescence melts to resolve 
multiple thermal transitions. Hence, first derivative plots of thermal transitions were used to 
delineate domain specific transitions of both protein-rich and -poor phases, which could not be 
obtained directly using DSC due to a clogging issue at high temperature by gelled highly 
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concentrated mAbs. The protein-rich phase of mAb Z had a lower Tm than its protein-poor 
phase by ~1.6 °C. The same trend was observed for mAb I, whose protein-rich phase is 
thermally less stable by ~ 3.9 °C (Tm1) and 1.2 °C (Tm2) than the protein-poor phase. 
Conversely, mAb H’s enriched phase showed higher Tm values than its protein-poor phase. Tm1 
of its protein-rich and protein-poor phases are 64.4 ± 0.1 and 61.1 ± 0.1 °C, respectively, 
although their Tm2 showed only a minor difference. The increase of Tm1 for mAb H may 
correspond the fact that the Tm1 of mAb H is below its critical temperature since mAb H likely 
has the strongest stabilizing PPIs of the three mAbs. 
Differences seen in their thermal unfolding profiles can result from the relative thermal 
stability of each domain and/or the cooperativity of their thermal unfolding events. For instance, 
mAb I showed a small early transition and a large second one. The first transition is often 
attributed to the unfolding of the CH2 domain because of its relatively low stability37, and the 
second one probably reflects a combination of the Fab and the CH3 domain. In contrast, the 
magnitude of mAb H’s first transition is comparable to the second one. This may suggest that 
mAb H has a relatively less-stable Fab, which contributes to the first transition alone or in 
combination with the CH2 domain. Since mAb H’s Tm1 increases in the protein-rich phase, this 
indicates that PPIs in protein-rich phase likely stabilize the mAb H’s Fab (supported by HDX 
data below). MAb Z showed one broad transition consisting of several overlapping peaks, 
indicating that domains of mAb Z thermally unfolds in a more cooperative manner. The first 
thermal transition of mAb I’s two phases shared a similar magnitude (Figure 4.6C). As mentioned 
above, such a transition may represent the thermal unfolding of the CH2 domain. This indicates 
that thermal unfolding of the CH2 domain in mAb I did not significantly disrupt PPIs in its 
protein-rich phase. Therefore the CH2 domain is probably not part of the PPI interface for mAb 
I (supported by HDX data below). 
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4.3.8 Static Light Scattering 
Static light scattering (SLS) was employed to monitor the aggregation of the two phases 
upon heating. Dynamic light scattering could not be used because of multiple scattering in high 
protein concentration solutions. SLS was measured with 450 nm light to avoid any absorption of 
lamp light by highly concentrated chromophores (Phe, Tyr, and Trp residues). As expected, 
protein-rich phases had higher SLS signals than corresponding protein-poor phases at 25 °C 
(Figure 4.7). Increasing temperature resulted in different trends in the pre-transition baselines of 
these three mAbs. For instance, both phases of mAb Z showed declining linear-like baselines, 
with the protein-rich phase decaying slightly faster. The protein-rich phase of mAb I also showed 
a decreasing baseline prior to its thermal transition. Its protein-poor phase, however, had a 
nearly flat baseline. In contrast, both mAb H’s two phases manifested flat pre-transition 
baselines, suggesting the interaction networks formed by mAb H are not as strongly affected by 
temperature. The differences seen in pre-transition baselines of the three mAbs can be 
attributable to the temperature dependence of their PPIs. MAb Z seems to show the highest 
temperature dependence and mAb H the lowest. This trend agrees with the temperature 
dependent phase behaviors illustrated in their coexistence curves (Figure 4.1).  
Protein-poor phases showed greater increases in their SLS signals during thermal 
transitions than the protein-rich phase for the three mAbs. Gelation upon thermal unfolding in 
the protein-rich phase could be responsible for reduced transmittance and the smaller changes in 
SLS signals during thermal transitions. We also noticed that the protein-rich phase of mAb I had 
an early transition starting at ~60 °C, which was not seen in its depleted phase. We attribute this 
transition to the unfolding induced aggregation of the CH2 domain, based on the DSC and 
fluorescence data discussed above. It suggests that the thermal unfolding of the CH2 domain of 
mAb I initiates aggregation in the protein-rich phase but not in the protein-poor phase, probably 
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because of the much higher protein concentration in the protein-rich phase. This early transition 
was, however, not observed for mAbs Z and H. 
4.3.9 Interface Mapping with HX-MS Analysis 
 For mAbs H and I, we performed HX-MS measurements to identify specific locations 
involved in protein-protein interactions. HX-MS was recorded as a function of exchange time 
(120 s, 103 s, 104 s, 105 s). Differences in HX-MS between protein at 60 mg/ml and protein at 5 
mg/ml, ΔHX, were determined (Figure 4.8). ΔHX < 0  (i.e., increased protection) therefore 
represents regions in which the antibody backbone at 60 mg/ml is less flexible than the protein at 
5 mg/ml. Sequences which exhibited substantial changes in protection are summarized in Table 
4.4.  
For mAb H, there were protected regions in the CDR L2 and the heavy chain framework 
region. Both antibodies exhibited significant protection in the variable regions. The protected 
regions of mAb H contain a relatively disproportionate number of charged amino acid residues 
(Table 4.4). The two protected sequences for mAb H contained amino acid residues of opposite 
charges, suggesting at least a partially electrostatically driven self-association. In a homology 
model, the positive and negatively charged patches reside on opposite faces of the variable 
domain as shown in a homology model (Figure 4.9) indicating that Fab-Fab domain interactions 
probably mediate reversible-self association in this case.  
 For mAb I, HX-MS analysis revealed protection in the VH region (at 120 s and 103 s) and 
in the VL and CH1 domains at 104 s. The sequences involved in the variable heavy chain are 
relatively hydrophobic and contain a high number or Trp and Tyr residues (Table 4.4). The 
isolated sequences have from 20 to 70 % aromatic residues, much greater than that found overall 
in the antibody itself which has only 8 % aromatic residues. 
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 Subtle differences in solution conditions may be important for the interpretation of the 
HX-MS results since HX-MS was performed in slightly higher ionic strength conditions than 
those for which proteins phase separate. A recent study performed HX-MS directly on phase 
separated antibody solutions and found that nearly half of the sequences in the peptide map 
exhibited some significant degree of protection38. The concentration differences from 60 mg/ml 
at which we performed HX-MS and the >200 mg/ml solutions may also result in increases in 
protection at more sites because of the increased protein volume fraction. Two previous studies 
from our group involving different antibodies have identified both Fab-Fab and Fab-Fc interfaces 
responsible for protein reversible self-association19,39. Here the interactions driving protein self-
association with these two mAbs were primarily identified in the variable regions.  
4.3.10 Size Exclusion Chromatography 
Size exclusion (SEC) chromatograms of the diluted protein phases displayed a preference 
for more dimer in the protein-rich phase and fragments in the protein-poor phase. There was 
2.2, 2.1 and 2.0 percent more dimer in the protein-rich phase than the protein-poor one for 
mAbs Z, H and I, respectively (Table 4.5). Fragments eluting at ~11.5 mL were observed for all 
three mAbs with the highest difference seen in mAb H, where 1 % more fragments were 
observed in the protein-poor phase. The chromatograms for mAb H and mAb Z also exhibited 
small shoulders on either side of the main peak (Figure 4.10). We hypothesize that the protein-
rich phase contains more aggregates because dimers can participate in the dynamic networks 
that drive phase separation while fragments only have one binding site and therefore could only 
exist at the edges of a network.  
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4.3.11 Aggregation Rates 
The two phases were separated and injected on to the column without any dilution to 
measure the aggregation rates for each phase at 40 °C. Since the protein-rich and protein-poor 
phases are in equilibrium, the two phases have identical chemical potentials. Aggregation kinetics 
are a function of the chemical potential of protein in solution, therefore we hypothesized that 
protein aggregation rates would be equivalent in both phases. 
One caveat is the difference observed in HMWS when directly injecting the protein-rich 
phase (4.5 % HMWS for mAb I at time zero) in comparison to diluting the protein-rich phase 
prior to injection (2.7 % HMWS for mAb I at time zero). This difference (4.5% without dilution 
to 2.7% following dilution) reflects that some fraction of the aggregates observed by SEC without 
dilution of the protein-rich phase are reversible. This was observed for all three immunoglobulins 
(most drastically for mAb H). Therefore the fraction of reversible and non-reversible aggregates 
at each time point could not be determined by SEC. Our analysis is simplified by interpreting 
HMWS as the sum of reversible and non-reversible aggregates. 
All three antibodies exhibited higher or equivalent aggregation rates in the protein-poor 
compared to the protein-rich phase (Figure 4.11). MAb Z’s protein-rich phase remained 
approximately constant in the amount of high molecular weight species (HMWS) for the two-
week period (Table 4.6). However, mAb Z’s protein-poor phase had an aggregation rate of 0.84 
%/wk. MAb H had two small decreases in amount of HMWS. A slower equilibration process in 
the protein-rich network could alter the fraction of HMWS at these time scales. The protein-poor 
phase of mAb H aggregated faster than the rich-phase at a rate of 0.58 %/wk. MAb I aggregated 
at equivalent rates in the protein-rich (0.82 %/wk) and protein-poor phases (0.78 %/wk). 
Typically aggregation rates increase with protein concentration since thermodynamic activity 
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increases with concentration, however all three mAbs in this study showed slower or equivalent 
rates in the protein-rich phase compared to the protein-poor phase.  
The clipping of antibody molecules happened more rapidly in the protein-rich phase than 
the protein-poor phase. Especially for mAb Z, whose protein-rich phase had a fragmentation rate 
of 5 %/wk and protein-poor phase a rate of 0.3 %/wk.  A major degradation pathway of 
antibodies at pH > 6 is fragmentation caused by base catalyzed beta elimination of Xaa-Cys 
residues in the hinge region40. The hydrogen abstraction required for this mechanism may be 
more energetically favorable for the GGG conformation only present in the protein-rich phase of 
mAb Z and explain the major discrepancy in the observed rates. For mAb H, the clipping rate 
was only slightly faster while for mAb I they were nearly equivalent.  The differences in disulfide 
structures in IgG4 (mAb Z) and IgG1 (mAb H and I) may be important for the differences in the 
observed clipping rate constants. This explanation is only speculative, however, and differences 
could also be the result of partitioning of some protease impurities into the protein-rich phase of 
mAb Z. 
4.4 Discussion 
Phase separation of protein solutions has become a well-recognized phenomena. Studies of 
proteins such as lens crystallins2,15,41, monoclonal immunoglobulins3,42 and a few other proteins 
have described the event in some detail in terms of temperature, pH and salt effects7. The 
structural state of proteins in each phase, however, has seen few studies. It might at first be 
assumed the state of the protein in each phase would be the same since they are present at 
thermodynamic equilibrium. But in a protein/water/buffer or salt system simple application of 
the phase rule is not possible. For example, proteins themselves exist in an equilibrium of many 
microstates which reflect the highly dynamic nature of protein structure. Thus, it is not a surprise 
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that characterization of these three immunoglobulins suggest differences in the structure and 
behavior of the proteins in each phase. Measurements of the water bend-liberation band suggests 
an increases in order of the hydrogen-bonding network of a portion of the water in the more 
concentrated protein phase. This is also expected since the increase in protein concentration will 
be accompanied by more water of hydration. The magnitude of this effect, however, seems to be 
too small to account for the observed changes in peak shift since no changes in band position 
were observed for water in the protein-lean phase. Self-association of the protein in the more 
concentrated phase would be expected to reduce hydrating water due to reduction in 
immunoglobulin surface area. Entrapment of water in aggregates offers another possibility. 
Is it possible that the apparent conformational changes seen are an artifact of any of the 
measurement processes? While we cannot entirely exclude this possibility, we think this is 
unlikely. Spectral artifacts such as inner filter effects in fluorescence, surface adsorption (minimal 
contribution at the high concentrations employed) and electrostatic effects due to unequal 
distribution of buffering ions all appear to be negligible. We think two other explanations are 
more likely. Shifts in the distribution of protein conformational states due to water activity and 
protein concentration could produce the effects seen and are consistent with conformational 
changes observed in phase separation43. More likely, however, is that the micro-aggregation 
states that appear to exist in concentrated immunoglobulin solutions8 could lead to structural 
alterations. The change seen in vibrational spectra and intrinsic fluorescence are consistent with 
this idea. The change seen in disulfide properties (dihedral angles) are consistent with the idea 
that changes in the dynamic nature of immunoglobulin may be involved in the spectral changes 
seen. Isotope exchange identifies regions for two proteins that form contact points for self-
association (we were unable to perform such studies for the third protein).  
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Theoretical models of protein aggregation predict increases in aggregation rates with 
increased protein concentration (activity) since the reaction is at least bimolecular44,45. 
Aggregation rates were slowed or equivalent for more highly concentrated solutions of all three 
phase separated antibodies herein.  This atypical observation results from the equivalent 
chemical potential of the protein-rich and protein-poor phases46. However, if solely chemical 
potential dictated aggregation rates one would anticipate equivalent aggregation rates in both 
phases for all three antibodies. However, only for mAb I were aggregation rates equivalent in 
both phases while for mAb H and mAb Z the aggregation rate was slower in the protein-rich 
phase. If aggregation is diffusion rate-limited the higher viscosity protein-rich phase could slow 
aggregation. An alternate explanation for why the aggregation rates are slower in the protein-
rich phase is that to form an irreversible aggregate two monomers must diffuse close together to 
form an encounter complex which needs to rearrange to form a stable aggregate nucleus. If the 
protein’s native state is stabilized by self-interaction or the proteins are constrained by crowding, 
the kinetics of forming a stable aggregate nucleus would be expected to be slower12.   
 Phase separation provides a unique opportunity to study aggregation rates at different 
protein concentrations but equivalent chemical potentials. Phase separation is known to promote 
aggregation in cells for some proteins14. We suspect however that in some cases the opposite may 
be true; the protein-rich droplets may serve to slow protein aggregation processes by slowing 
diffusion and/or stabilizing a proteins native state. Conformational changes of proteins in the 
protein-rich phase may alter other cellular reaction kinetics similar to the increased rate of 
clipping for mAb Z. 
4.5 Conclusion 
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We have observed several consistent conformational changes in all three mAbs when 
comparing their protein-rich and protein-poor solutions of phase-separated antibodies. 
Tryptophan emission and vibrational spectra suggest conformational changes of proteins in 
dynamic clusters. Disulfide bond isomerized to higher energy conformations further confirmed 
changes in the dynamic nature for all three immunoglobulins in the protein-rich phase. These 
changes persisted in temperatures well above the coexistence curve but not above the Tm 
indicating that thermal unfolding disrupts the interactions governing phase separation. The 
hydrogen bond network of water was significantly more ordered in the protein-rich phase 
indicating a possible role for water in the dynamic clusters. Our measurements also highlight the 
utility of techniques which can characterize protein phases directly without the need for dilution. 
HX-MS identified specific sequences of the protein involved in the protein-protein interfaces and 
indicated a role for non-covalent ionic and hydrophobic interactions on the Fab for mAb H and 
I, respectively, leading to reversible protein-protein interactions in a concentration dependent 
manner. Protein aggregation was slowed in the protein-rich phase relative to the protein-poor 
phase for mAb’s H and Z while aggregation rates were equivalent for mAb I.   
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4.7 Figures and Tables 
Table 4.1. The mAb concentrations and buffer conditions used throughout this study. Measured 
concentrations and pH for each phase. 
Protein sample 
(isotype) 





20 mM histidine,  
pH 6.8 
Protein-poor 35.0 ± 0.1 6.80 ± 0.10 




20 mM sodium 
phosphate, pH 7.5 
Protein-poor 8.9 ± 0.1 7.51 ± 0.04 




5 mM sodium 
phosphate, pH 8.0 
Protein-poor 19.9 ± 0.1 8.00 ± 0.01 





Table 4.2. Critical concentration, temperature and coexistence width for antibody phase 
coexistence curves. Cc and Tc are the respective concentration and temperature at the critical point of 
the best fit coexistence curves. A parameterizes the width of the coexistence curve. 
mAb (isotype) Cc (mg/ml) Tc (°C) A 
mAb Z (IgG 4) 133.8 ± 3.3 29.8 ± 1.9 2.14 ± 0.14 
mAb H (IgG 1) 129.0 ± 1.6 85.9 ± 28.7 1.60 ± 0.16 





Figure 4.1. Liquid-liquid coexistence curves of mAbs Z, H, and I reflecting their temperature 
dependent LLPS behavior. Error bars represent the standard deviation of three experiments. Lines 




Figure 4.2. Raman spectra for mab Z (top panels), mab H (middle panels) and mab I (bottom 
panels). Left column displaying the spectral region associated with SS stretching vibrations, middle 
column – tyrosine Fermi doublet, and right column the amide I band. See Table 4.1 for protein 





 Table 4.3. Summary of Raman data. 
mAb Phase SS ratio 
I540/510 
Tyr ratio I855/830 Amide I mean Amide I 
FWHM 
Z Protein-poor 7.37 ± 0.70 1.42 ± 0.02 1663.3 ± 0.1 34.4 ± 0.1 
Z Protein-rich 2.41 ± 0.04 1.39 ± 0.02 1664.3 ± 0.1 33.7 ± 0.1 
 
H Protein-poor 1.15 ± 0.31 1.77 ± 0.03 1663.2 ± 0.5 35.3 ± 0.3 
H Protein-rich 2.12 ± 0.12 1.57 ± 0.01 1664.3 ± 0.1 33.7 ± 0.1 
 
I Protein-poor 1.11 ± 0.22 1.28 ± 0.02 1664.3 ± 0.1 33.8 ± 0.1 





Figure 4.3. (A) FTIR bend-liberation combination bands of water in the two liquid phases of mAb 
samples and (B) their mean frequency between 1900 and 2300 wavenumbers cm–1. See Table 4.1 for 




Figure 4.4. FTIR spectra vs temperature of the three antibodies for both the protein-poor and 
protein-rich phases. Vertically offset spectra represent increasing temperatures. See Table 4.1 for protein 




Figure 4.5. FTIR amide I peak position vs temperature for each of the antibodies in protein-poor 
and protein-rich phases. The error-bars represent the standard deviation of three independent 
measurements. See Table 4.1 for protein concentrations and solution conditions. 
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Figure 4.6. Thermal stability of the proteins in the two liquid phases of the mAb samples measured 
by intrinsic tryptophan fluorescence spectroscopy. The mean fluorescence emission wavelength (λμ) of 
(A) mAb Z, (B) mAb H and (C) mAb I. See Table 4.1 for protein concentrations and solution conditions. 





Figure 4.7. Static light scattering vs temperatureof the protein-rich and protein-poor phases of (A) 




Table 4.4. Sequences of self-associating interfaces for mAb H and mAb I as determined from HX-
MS analysis (Figure 4.8). 
mAb Region Sequence % Positive % Negative % Aromatic 
H CDR L2 VLIVFDDEDRPSGIP 7 27 7 
H H chain FWR KKPGASVKVSCKAS 29 0 0 
H 
 
Entire sequence 11 9 9 
I CDR H1 YYWSWI 0 0 67 
I CDR H2 SLYYSGSTYYNP 0 0 33 
I CDR L1 SQGISSWLAWYQQ 0 0 23 





Figure 4.8. HX mass differences for mAb H and mAb I at four labeling times comparing high (60 
mg/ml) and low (5 mg/ml) protein concentrations. The difference in the Y-axis displays the value of 
deuterium uptake at high protein concentration minus that at low protein concentration. Negative values 
indicate slower hydrogen exchange at high protein concentration. The dashed horizontal lines are the 
99% confidence criterion. Three independent HX measurements was performed. Different domains are 
assigned based on peptide region and listed at the top of each plot. 
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Figure 4.9. Homology models of the variable domains of mAb H (left) and mAb I (right). Residues 
regions that become substantially protected from HX at 60 mg/mL are shown with sidechains and in color. 
Regions with aromatic side-chains  are shown in green, positively charged side-chains are shown in blue 





Figure 4.10. SEC chromatograms of the three mAbs in the poor and rich phases. Samples were 
diluted to 1 mg/ml before injection on the column. Absorbance was measured at 280 nm. The y-axis has 
been scaled to show the difference observed in the dimer and fragment peaks for each antibody. The 




Table 4.5. Initial percent of species observed at 25 °C after phase separation by SEC. The 
standard deviation on these measurements is ± 0.1%. 
mAb Phase % Monomer % Dimer % Fragments 
Z Protein-poor 99.4 0.5 0.1 
Z Protein-rich 97.6 2.3 0.1 
H Protein-poor 97.5 1.2 1.3 
H Protein-rich 96.3 3.3 0.4  
I Protein-poor 99.0 0.7 0.3 




Figure 4.11. Size fractions of mAbs for the protein-poor and protein-rich phases during a two week 





Table 4.6. Rates of changes in % per week of species observed with SEC chromatography at 40 
°C. 
mAb Phase HMWS (%/ wk) Monomer (%/wk) Clips (%/wk) 
Z Protein-poor 0.84 ± 0.01 -1.16 ± 0.06 0.31 ± 0.06 
Z Protein-rich -0.01 ± 0.04 -5.08 ± 0.28 5.09 ± 0.03 
H Protein-poor 0.58 ± 0.02 -1.06 ± 0.03 0.48 ± 0.01 
H Protein-rich -0.55 ± 0.06 -0.28 ± 0.06 0.83 ± 0.03 
I Protein-poor 0.78 ± 0.02 -1.04 ± 0.03 0.27 ± 0.01 






Figure 4.S1. Raman spectra for mAb I protein-poor and protein-rich phases. All major peaks are 





Figure 4.S2. FTIR amide I spectra of both upper and bottom phases of mAb Z (A1), mAb H (B1), 
and mAb I (C1). The second derivative FTIR spectra of the two phases for mAb Z (A2), mAb H (B2), and 




Figure 4.S3. Thermal stability of mAbs measured by intrinsic fluorescence spectroscopy. 
Temperature dependent normalized fluorescence intensity of mAb Z (A1), H (A2), and I (A3). The first 
derivative curves of mAb Z (B1), H (B2), and I (B3). Melting temperatures are listed in a tabular form 




Figure 4.S4. Representative SEC chromatograms for each antibody phase over two weeks at 40 
°C. The figure on the left is the protein-poor phase for each antibody. The figures on the left has an arrow 
indicating the direction of time (chromatograms correspond to approximately every two days). The figures 
on the right have arrows indicating the assignments of HMWS, monomer and clipped species. All species 




Table 4.S1. Melting temperatures for each phase of each mAb from intrinsic tryptophan 
fluorescence melts. 
mAb Phase Tm1 Tm2 
Z Protein-poor 68.2 ± 0.1 NA 
Z Protein-rich 66.6 ± 0.1 NA 
H Protein-poor 61.1 ± 0.1 77.3 ± 0.2 
H Protein-rich 64.4 ± 0.1 78.3 ± 0.1 
I Protein-poor 65.1 ± 0.5 83.0 ± 0.5 




5 pH-Dependent Phase Behavior and Stability of Cationic Lipid–mRNA 
Nanoparticles 
5.1 Introduction 
Until recently the primary concern of gene therapy has been the ability to deliver sufficient 
coding nucleic acids to cells in vivo. The successful approval of the Onpatro lipid nanoparticle 
(LNP) formulation of siRNA to treat transthyretin-induced amyloidosis brings hope that nonviral 
vectors have begun to overcome the delivery barrier1. mRNA–LNPs are being investigated for a 
variety of disease indications from vaccines to protein replacement therapies2–5. Compared to 
viral vectors, mRNA–LNPs do not have major issues with immunogenicity of the particles and 
are inherently nonreplicating.  
A critical step enabling therapeutic use of mRNA–LNPs was the addition of cationic lipids 
with a pKa between 6.2 and 7 to greatly increase their transfection efficiency6–8. Following 
cellular uptake of lipid nanoparticles into endosomes there is a decrease in their pH. The 
decrease in endosomal pH results in the protonation of the cation lipid and association of the 
cationic lipid with anionic lipids in the endosomal membrane resulting in bilayer disruption and 
release of RNA into the cytoplasm3.  
mRNA–LNPs are formed by the rapid mixing of an organic phase containing a cocktail of 
lipids with an aqueous phase containing mRNA below the pKa of the ionizable lipid (here we 
use dilinoleylmethyl-4-dimethylaminobutyrate (DLin-MC3-DMA)). In the organic phase there 
are additional lipids: 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), cholesterol, and 1,2-
dimyristoyl-sn-glycerol-methoxy poly(ethylene glycol) 2000 (PEG-DMG 2000). The core of 
mRNA–LNPs primarily consist of mRNA complexed with the ionizable lipid along with 
cholesterol9–12. Generally the PEG lipid and DSPC decorate the outside of the particles and the 
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PEG lipid prevents non-specific interaction of mRNA–LNPs. The effect of pH on mRNA–LNPs  
structure has implications both for their cellular uptake mechanism and for the design of a stable 
liquid formulation.   
Typically the only physical traits of mRNA–LNPs which are characterized are size, zeta 
potential and pKa6,7,13. These traits can be varied by altering the lipids or their fractional 
composition and screened for efficacy. There have also been some more thorough 
characterizations using small angle scattering methods, cryo-TEM, and NMR which provided 
more detailed structural information to guide the rational design and formulation of LNPs9–12. 
However, these techniques are generally low-throughput and thus cannot be easily applied to 
characterize mRNA–LNPs across many solution conditions. Our lab has developed an approach 
using lower resolution techniques with a much higher throughput to generate empirical phase 
diagrams (EPDs)14,15. An EPD is a visual summary of the behavior of a macromolecule across 
solution conditions of interest. This permits analysis of hundreds of distinct conditions to better 
understand the behavior of macromolecules as a function of solution variables such as pH, ionic 
strength, and temperature. Our group has previously applied this approach to characterize 
cationic lipid-DNA complexes, liposomes, and a variety of other macromolecules15–17.  
To investigate the effects of complexation of mRNA and cationic lipids in LNPs we here 
characterize: EGFP mRNA, LNPs (without mRNA), and EGFP mRNA–LNPs. First we used 
DLS, zeta potential, and pKa determination by TNS fluorescence to understand basic physical 
properties. Next, to evaluate the phase behavior of the lipids a function of pH and temperature 
we used a combination of FTIR and differential scanning calorimetry (DSC). Circular dichroism 
and DSC are employed to probe tertiary structure and stability of EGFP mRNA. Optical density 
measurements are used to evaluate the colloidal stability of the mRNA–LNPs. These results are 
then visually summarized by an EPD. A six-week stability study of the mRNA–LNPs at 4 °C and 
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25 °C was used to evaluate the correlation between the biophysical measurements and the 
stability of mRNA–LNPs. Time-dependent pH-jump experiments were performed to evaluate 
the rate and reversibility of pH changes on the solution structure of mRNA–LNPs.  
5.2 Materials and Methods 
5.2.1 Materials 
Enhanced green fluorescent protein (EGFP) mRNA was purchased from Trilink 
Biotechnologies (San Diego, USA). The ionizable cationic lipid O-(Z, Z, Z, Z-heptatriaconta-
6,9,26,29-tetraem-19-yl)-4-(N,N-dimethylamino)butanoate (DLin-MC3-DMA) was synthesized 
by AstraZenaca. 1,2-dis-tearoyl-sn-glycero-3-phosphocholine (DSPC) was purchased from Avanti 
polar lipids. 1,2-Dimyristoyl-rac-glycero-3-methylpolyoxyethylene (PEG-DMG 2000) was 
purchased from NOF Corporation. Water was treated with diethyl pyrocarbonate (DPEC) prior 
to use.  
5.2.2 LNP synthesis 
LNPs were prepared using a microfluidic setup previously described in greater detail18. 
Briefly, EGFP mRNA was dissolved in 20 mM acetate at pH 4. A 50:10:38.5:1.5 ratio of Dlin-
MC3-DMA:DSPC:Chol:PEG-DMG2000 was dissolved in ethanol. The lipid mixture was 
combined with a 50 mM citrate buffer (pH 4.0) containing mRNA at a ratio of 3:1 (aqueous : 
ethanol) using a microfluidic mixer (Precision Nanosystems, Vancouver, CA). Empty lipid 
nanoparticles were formed by using a citrate buffer without mRNA in the aqueous phase. 
Following mixing of the organic and aqueous phases, samples were immediately diluted 1000× 
into PBS (pH 7.4) with Amicon centrifugal filters (EMD Millipore). Following dialysis into PBS, 
samples were dialyzed against citrate-phosphate buffer at pH 4, 5, 6, 7, and 8. Citrate-phosphate 
(CP) buffer was prepared at 20 mM at pH 4.0, 5.0, 6.0, 7.0, and 8.0 from citric acid anhydrous 
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and sodium phosphate dibasic anhydrous. The ionic strength of each buffer was controlled to I = 
0.15 M by the addition of NaCl. Formulations were concentrated with Amicon centrifugal filters 
(EMD Millipore) to an RNA concentration of 0.1 mg/ml, filtered with a 0.22 μm filter and 
stored at 4 °C until use. LNP were concentrated to the same lipid concentration (2 mg/ml) as 
mRNA–LNPs. All experiments comparing mRNA–LNPs and LNPs kept the concentration of 
lipids constant. The encapsulation efficiency and concentration of mRNA was determined using 
the Ribo-Green assay (ThermoFisher, Waltham, MA). 
5.2.3 In Situ Determination of pKa with TNS 
6-(p-toluidino)-2-naphthalenesulfonic (TNS) acid sodium salt in DMSO (Sigma-Aldrich, St. 
Louis, MO) was prepared as a 100 μM stock solution in distilled water. An aliquot of the TNS 
solution was added to give a final concentration of 1 μM and following vortex mixing 
fluorescence intensity was measured at room temperature using a SpectraMax M5 
spectrophotometer employing an excitation wavelength of 325 nm and emission wavelength of 
435 nm. A sigmoidal fit to the fluorescence data was used to determine the pKa of the LNPs at 
the pH of the inflection point. 
5.2.4 Zeta Potential 
The zeta potentials of the LNPs were determined by phase analysis light scatting (PALS) at 
a scattering angle of 15 at 25° C with a Zeta PALS instrument (Brookhaven Instruments Corp., 
New York, USA). An electric field strength between 14 and 16 V/cm was used. Data were 
collected with 10–15 cycles of the electric field for each experiment and averaged. Zeta potential 
was calculated using the measured electrophoretic mobility with the Smoluchowski 
approximation. 
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5.2.5 Dynamic Light Scattering 
A DynaPro II Plate Reader (Wyatt Technology, Santa Barbara, CA) was employed for 
dynamic light scattering measurements. Incident light was detected in a backscattering geometry 
and analyzed with an autocorrelator. A clear-bottomed 384 well plate holding 20 μL of sample 
was read at 20 °C. Samples were measured 5 times with a 15 second acquisition time. Cumulant 
analysis was used to determine hydrodynamic radius and polydispersity. Errors are reported as 
standard deviation of 3 replicates.  
5.2.6 Kinetic DLS experiments 
For kinetic experiments all samples were diluted 100x from a concentration of 0.1 mg/ml 
mRNA prior to size measurement. There were four samples in this experiment, two initially at 
pH 6 and two initially at pH 8. One of the pH 6 samples was diluted into pH 6 and the other 
diluted into pH 8. One of the pH 8 samples was diluted into pH 6 and the other diluted into pH 
8. Samples were measured in triplicate. It took approximately two minutes following dilution 
before the first size measurement was completed. Experiments were performed in triplicate. 
5.2.7 Circular Dichroism 
An Applied Photophysics Chirascan (Leatherhead, UK) with a six-cylinder cuvette holder 
was used to record circular dichroism spectra. Two hundred microliters of sample were placed in 
quartz cuvettes with a 1 mm pathlength at a concentration of 0.1 mg/ml RNA. Spectra were 
recorded from 200 to 300 nm in 1 nm steps. Samples were baseline corrected by subtracting their 
corresponding buffer. For temperature melts samples were capped using Teflon stoppers and 
measured every 2.5 °C from 10 to 90 °C. 
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5.2.8 Differential Scanning Calorimetry 
Differential scanning calorimetry was performed using a Malvern Microcal VP-Capillary 
calorimeter (Malvern, UK). Samples were placed in a 96 well plate and held in an autosampler at 
4 °C prior to measurement. The temperature was increased at ramp rate of 1 °C/min from 10 to 
100 °C. Samples were buffer subtracted, baselined, and normalized for concentration using 
Origin 7.0 (Origin Lab, Northampton, MA).  
5.2.9 FTIR Spectroscopy 
FTIR measurements were performed with a Tensor-27 FTIR spectrometer (Bruker, 
Billerica, MA) using a Bio-ATR cell. Samples were concentrated to 1 mg/ml RNA. The detector 
was cooled with liquid N2 for 20 min before use. During this time the interferometer was also 
continuously purged with N2 gas. Spectra were obtained from 800 – 4000 cm–1 with a resolution 
of 4 cm–1. For the thermal melting experiments, 64 scans were obtained, and samples were 
scanned from 10 to 90 °C using an increment of 2.5 °C/step and an equilibration time of 2 min 
at each step. Raw FTIR spectra were buffer subtracted, water vapor and CO2 compensated, 
baseline corrected, and normalized using the OPUS V6.5 software (Bruker, Billerica, MA). Peak 
positions were determined using in-house python scripts. For the peaks originating from CH2 
wagging, peak intensities were monitored by normalizing to the neighboring CH3 umbrella peak. 
5.2.10 Optical Density  
Thermal aggregation of mRNA–LNPs was monitored using a Cary 100 UV-Visible 
spectrophotometer (Aligent Technologies, Santa Clara, California) equipped with a 12-cell 
temperature controlled Peltier device. Samples were placed in quartz cuvettes (1 cm path length) 
at a concentration of 0.1 mg/ml mRNA. The temperature was ramped from 10 to 90 °C in 2.5 
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°C increments with a 120 s equilibration time. Optical density was recorded at 450 nm (a non-
absorbing region of the spectrum). 
5.2.11 Phase Diagram 
Phase diagrams were prepared as previously described15,19. Briefly, a singular value 
decomposition was applied to a matrix containing data from FTIR, DSC, optical density, and 
circular dichroism. The top three values of the SVD were each normalized and represented by a 
red, green, or blue color value. At each pH and temperature, a tuple of these three values was 
used to set an RGB color for empirical phase diagram visualization. 
5.2.12 Transfection Efficiency 
HeLa cells were grown in DMEM supplemented with 100 mL/L of FBS, 10 IU/mL of 
penicillin, and 10 mg/mL of streptomycin. The cells were incubated at 37 °C in a 5% CO2 
environment and subcultured by partial digestion with 0.25% trypsin and 
ethylenediaminetetraacetic acid. Cells were passaged at ∼80% confluence. HeLa cells were 
seeded at 15,000 cells per well in a black 96-well plate. Cells were then washed off the plates and 
suspended in a volume of 0.2 mL media which was used for FACs and fluorescence microscopy. 
Agarose RNA gels (ThermoFisher Scientific) were run to determine the quality of the mRNA 
within the LNPs. 
5.2.13 mRNA–LNP Stability 
One mL of mRNA–LNPs formulated in citrate phosphate were stored at either 4 or 25 °C 
for up to 6 weeks. At each timepoint an aliquot was pulled from the sample to measure 
hydrodynamic radius, polydispersity, transfection efficiency, mRNA concentration, mRNA 
encapsulation efficiency, and mRNA integrity.  
5.3 Results 
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5.3.1 pKa, Size, and Zeta Potential 
We first addressed the most commonly characterized aspects of mRNA–LNP structure: 
pKa, size and zeta potential. The pKa of the mRNA–LNPs was found to be 6.43 in Figure 5.1A, 
in good agreement with previous results for DLin-MC3-DMA7. The hydrodynamic radius of the 
mRNA–LNPs was similar for pH 4, 5 and 6 at ~46 nm, while the mRNA–LNPs at pH 7 and 8 
were ~35 nm (Figure 5.1B). LNPs were smaller, with radii near 28 nm which was fairly 
consistent across pH. EGFP mRNA alone had a radius ~ 12 nm which did not change 
significantly with pH (Figure 5.S1). The mRNA–LNPs zeta potential decreased from 20 to -20 
mV as pH increased from 4 to 8. Zeta potential valus shown in Figure 5.1C was similar for 
mRNA–LNPs and LNPs. The LNPs decreased in zeta potential faster as pH increased but at pH 
4 and 8 the LNPs and mRNA–LNPs had equivalent zeta potential. 
5.3.2 Circular Dichroism 
Circular dichroism (CD) of mRNA arises from the double stranded regions which are 
distinctly coiled depending on the interactions of base pairs. The CD spectra of EGFP mRNA 
has maxima at 262 and 223 nm and minima at 209 and 247 nm (Figure 5.2A). This is consistent 
with the A form of mRNA which has a maximum around 260 nm, a shoulder at 220 nm and a 
minimum near 210 nm20,21. mRNA does not typically adopt the B form because of the 
unfavorable steric clash of the 2-OH with the 3`-OH. mRNA can adopt B form conformations 
but because it is unfavorable typically less than 5% of structures are in conformations similar to B 
form22. The minima at 247 nm becomes more pronounced and red shifts ~3 nm for EGFP 
mRNA at higher pH. This indicates a conformational equilibrium between the A and B forms 
with the percentage of B-form like structures increasing at higher pH for EGFP mRNA free in 
solution. 
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mRNA–LNPs also show a pH dependent shift in mRNA structure (Figure 5.2B). At pH 
below the pKa of the mRNA–LNPs the CD signal becomes more negative. This shift indicates 
an increasingly favored A form mRNA at lower pH. At higher pH the RNA CD spectra are 
similar to those of EGFP mRNA in solution. This suggests that ionic interactions of Dlin-MC3-
DMA and RNA induce more A form in EGFP mRNA. Measurements of EGFP LNPs below 220 
nm were hindered by the CD signal from the lipids (absorbing double bonds) while above 220 
nm the spectra of LNPs did not exhibit signal as shown in Figure 5.S2. 
CD melts performed to compare the stability of mRNA tertiary structure in solution with 
the structure inside the mRNA–LNPs are shown in Figure 5.2C and 5.2D. mRNA in solution 
exhibited a gradual loss of structure as temperature was increased at pH 6, 7 and 8.  For pH 4 
and 5, along with the gradual loss of structure there were sharper transitions at ~ 40 °C and 85 
°C, respectively. For mRNA–LNPs at all pH conditions there were several gradual transitions as 
a function of temperature. For pH 4 and 5 there was a large increase in the CD signal which 
corresponded to the aggregation of the nanoparticles (discussed in later the optical density 
section) 
5.3.3 Differential Scanning Calorimetry 
Differential scanning calorimetry (DSC) was employed to understand the thermally inducd 
structural transitions of mRNA and lipids. mRNA typically has thermodynamic transitions 
associated with the unraveling of hydrogen-bonded regions. DSC can detect the coming apart of 
these regions as enthalpic peaks in a DSC thermogram. EGFP mRNA exhibited many distinct 
and overlapping thermal transitions at each pH as shown in Figure 5.3A. The mRNA unfolding 
curves for each pH differed significantly in the transition temperatures and enthalpies indicative 
of highly pH dependent stability. DSC was able to resolve multiple discrete transitions that CD 
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was not sensitive enough to identify. pH 4 and 5 exhibited sharp peaks at 40 and 85 °C which 
were distinct from the thermograms of pH 6, 7 and 8. These peaks agree well with the sharp 
transitions observed for pH 4 and 5 using circular dichroism shown in Figure 5.2C.  
DSC of LNPs (without mRNA) as shown in Figure 5.3C exhibited no transitions except at 
pH 5 and 6. For pH 5 there was a large broad transition with a maximum at ~65 °C. At pH 6 
there is a similar transition at 25 °C. For mRNA–LNPs (Figure 5.3B) only one transition was 
observed at pH 7 and 8, while pH 6 had two transitions, where pH 5 had one transition, and pH 
4 lacked transitions. The transition for pH 5 and the first transition for pH 6 are similar to those 
observed for the empty LNPs. We assign these peaks to inverse hexagonal to lamellar phase 
transitions (further supported by FTIR, see below). There is a transition of similar width and 
magnitude for pH 6, 7, and 8 at 72, 68, and 65 °C, respectively. This transition may arise from 
the dissociation of mRNA and cationic lipids. This hypothesis is also supported by the small 
negative feature seen by CD in Figure 5.2D for pH 6, 7 and 8 at similar temperatures since one 
might expect a change in mRNA structure following disassociation. The cationic lipid would 
become increasingly charged at low pH which could explain the increase in transition 
temperature and eventual disappearance of this transition since at pH 4 and 5 the ionic 
interactions between DLin-MC3-DMA and mRNA may be strong enough prevent dissociation 
at high temperature. For all pH conditions the individual transitions of the RNA were no longer 
observed, suggesting the RNA and lipid phase transitions become coupled upon complexation. 
5.3.4 Optical Density 
The colloidal stability of the mRNA–LNPs was assessed by measuring solution optical 
density as a function of pH and temperature. Increases in optical density in Figure 5.4 
correspond to aggregation of the mRNA–LNPs. Optical density was monitored at 450 nm so 
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that all observed optical density changes could be attributed to scattering. Aggregation began at a 
lowest temperature at pH 4 of near 65 °C. At pH 5 this increased to around 73 °C and at the 
higher pH values of 6, 7 and 8 the mRNA–LNPs did not aggregate until approximately 80 °C.  
5.3.5 FTIR Spectroscopy 
FTIR is able to probe the phase behavior and conformation of lipids in bilayers23. FTIR 
spectra for mRNA–LNPs from pH 4 to 8 are shown in Figure 5.4A. We assume the FTIR signal 
arises from lipids although a small fraction of the signal does originate from the mRNA (20 : 1 
mass lipids to mRNA). The C-N stretching band near 1200 cm–1 blue shifts with increasing pH 
as shown in Figure 5.4B. This peak is indicative of the pKa of the amine group and did not 
change significantly with temperature. To evaluate the lipid phase organization and geometry, 
the C=O stretching peak was followed as a function of pH and temperature in Figure 5.4C. An 
increase in C=O stretching frequency of approximately 4 cm–1 indicates an inverse hexagonal to 
lamellar phase transition23. At pH 4 and 5 the C=O stretching frequency has a value of ~1729.5 
cm–1 while at pH 7 and 8 the initial value of the C=O stretching frequency is 1732.5 cm–1. This 
suggests that at pH 4 and 5 the organizational structure of the lipids is inverse hexagonal while at 
pH 7 and 8 the structure of the lipids is lamellar. At pH 6 the initial value of the C=O stretching 
frequency is 1731 cm–1 which suggests a mixture of the two phases. As temperature increases, a 
transition between inverse hexagonal phase and a lamellar phase was observed at pH 5. At pH 6 
a similar transition was observed but the magnitude of the shift was smaller since the initial C=O 
stretching band position was already somewhere in-between the two. This is in good agreement 
with the transition observed by DSC at pH 5 and 6 since at pH 5 the transition has a large 
magnitude and at pH 6 a similar but smaller magnitude transition was observed.  
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The CH2 scissoring band position and contour is determined by the lateral interchain 
interactions of methylene chains and is sensitive to the organizational structure of lipids in 
assemblies. The CH2 scissoring band observed for the mRNA–LNPs has one main peak (not 
split) which is consistent with inverse hexagonal or lamellar structure. The peak position was 
1466 cm–1 at pH 4 and gradually decreased to 1464.5 cm–1 at pH 8. For all pH conditions there 
is a gradual decrease in the peak position with an increase in temperature as shown in Figure 
5.4D. Though this band can sometimes be used to directly assign the organizational structure 
lipid subcells, it can be interfered with by end-methyl groups in hydrocarbon chains. Thus, we 
relied more heavily on C=O and DSC to assign the lipid phase organizational structure. The fact 
that this peak is not split to supports our phase assignments. 
The CH2 wagging peaks are indicative of the nonplanarity of the CH2 bonds of the carbon 
chains.  The three bands which arise from non-planarity are kink (gtg), double gauche (gg), and 
end gauche (tg). In Figure 5.4E the intensity of the gtg peak at 1367 cm–1 has been normalized to 
the methylene umbrella at 1378 cm–1 for all pH and temperatures. At low pH the gtg peak height 
is ~0.75 while at high pH it is ~0.92 indicating a higher fraction of kinked gauche CH2 groups at 
higher pH. As temperature increased both pH 5 and 6 saw a gradual increase in the fraction of 
kinked CH2 groups which coincided with the transition from inverse hexagonal to lamellar. The 
transition from inverse hexagonal to lamellar also coincided with the observation that mRNA–
LNPs are approximately 14 nm smaller in diameter at pH values below the pKa suggesting that 
the phase of the lipids and their size are linked. The increased kinks in the CH2 groups may be 
responsible for the increase in size of mRNA–LNPs at low pH since the apolar chains cannot 
pack together as tightly. 
The methylene symmetric (svCH2) and asymmetric stretching modes (asvCH2) give rise to IR-
active bands at 2850 and 2920 cm–1. The methylene stretching modes are shown for all pH 
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conditions in Figure 5.S2A. The svCH2 band is relatively free from contributions of CH3 groups 
and is sensitive to the conformal disorder of trans methylene chains. A conformational 
disordering of the lipid structure is associated with the increase is this peak position. Figure 5.S2B 
depicts the svCH2 peak position as a function of temperature and pH. At 10 °C the svCH2 band has a 
maximum of 2852.5 cm–1 for pH 4 and increases with pH to 2853.5 cm–1 at pH 8, indicating an 
increase in conformational disorder at higher pH. Since DLin-MC3-DMA will be less ionized at 
higher pH, the nonionic fraction will act as a solvent to some extent, which leads to the increase 
in disorder of the system. All pH conditions saw a gradual increase in peak position as with 
increasing temperature as well. 
5.3.6 Empirical Phase Diagram 
An EPD was used to visually summarize the solution behavior of mRNA–LNPs from 15 to 
90 °C and pH 4 to 8. The EPD for mRNA–LNPs in Figure 5.5 has at least six distinct regions. 
Tentative assignments for the regions are as follows: (I) inverse hexagonal phase and more A 
form RNA, (II) lamellar phase, (I / II) transition region from region I to region II,  (III) 
aggregated particles with inverse hexagonal structure, (IV) a lamellar lipid phase with 
disassociated RNA and cationic lipids, and (V) aggregated particles with lamellar phase lipids. It 
is important to recognize that the EPD is not meant to reflect equilibrium since some of the 
process involved here are not reversible. 
5.3.7 Accelerated Stability Study 
To understand the effect of pH on lipid nanoparticle stability an accelerated stability study 
was performed. Samples were held at 4 and 25 °C for up to six weeks with timepoints every 
week. Transfection efficiency of HeLa cells was assessed using fluorescence activated cell sorting 
(FACs) and fluorescence microscopy. Transfection efficiencies varied significantly with pH even 
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at time zero (Figure 5.6A, E). Transfection efficiency at time zero decreased as pH increased 
from 85 % at pH 4 and 5 to a pH 8 mRNA–LNPs transfection efficiency of just under 40%. 
Differences in transfection efficiency as a function of pH at time zero suggest the inverse 
hexagonal structure mRNA–LNPs at low pH are able to traffic more mRNA to the cytosol. In 
general FACs results were well supported by the fluorescence microscopy data, examples of 
microscopy results are shown in Figure 5.S7.  
For storage at 4 °C, pH 4 and 5 slowly lost transfection efficiency over the course of six 
weeks but still retained transfection efficiency near 50% at the final six-week timepoint (Figure 
5.6A). For pH 6, 7, and 8 mRNA–LNPs failed to transfect a significant number of cells at the 
four-week timepoint. To understand the loss in transfection efficiency a ribogreen assay was 
performed to analyze RNA concentration and encapsulation efficiency, an RNA gel was run to 
assay the integrity of the RNA, and dynamic light scattering was performed to measure the 
colloidal stability at each timepoint. For the mRNA–LNPs at 4 °C the mRNA concentration and 
encapsulation efficiency were constant throughout the study (Figure 5.6B, C). The RNA gel for 
each timepoint are shown in Figure 5.4. Marker bands from ribosomal RNA in the far-left lane 
are the 18S (1.8 kilobases) band and approximately twice as dark 28S (4.7 kilobases) band. At 
time zero the RNA gel is similar for all pH values, showing one main band just past the 18S 
marker, in good agreement with the size of EGFP size of 996 bases. After one week a second 
band appeared at all pH near the 28S marker. This band could be from an mRNA multimer or 
lipid-bound mRNA. The total area of the RNA band was integrated in Figure 5.S6 for each 
timepoint which remained approximately constant for pH 4 and 5 but for pH 6, 7 and 8 
decreased and the loss of the RNA increased with pH. The size and polydispersity of the 
mRNA–LNPs remained approximately constant over the six-week period as shown in Figure 
5.6D and Figure 5.S8, respectively.   
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Storage of the mRNA–LNPs at 25 °C for one week resulted in a complete loss of 
transfection efficiency for pH 6, 7, and 8. At pH 4 after one week the complexes could only 
transfect ~10% of cells while at pH 5 they could only transfect ~5% of cells. For both pH 4 and 
5 all transfection efficiency was lost after two weeks. At 25 °C there was a significant loss of 
mRNA as measured by the ribogreen assay (Figure 5.6F). This loss correlated well with mRNA 
gels shown in Figure 5.S5 (quantified in Figure 5.S6B). However, at pH 5, 6, and 7 the mRNA 
that remained was still encapsulated within the LNP (Figure 5.6G). At pH 4 significant 
aggregation of the particles was observed after four weeks (Figure 5.6H). For pH 7 and 8 an 
increase of approximately 10 nm in radius was observed. Overall the mRNA–LNPs exhibited 
poor stability at 25 °C.  
5.3.8 Kinetics of mRNA–LNPs Phase Transitions 
To understand why a higher transfection efficiency occurred below the pKa of the 
mRNA–LNPs, we performed a kinetic analysis of the phase transition upon pH change using 
DLS to track the size change associated with the inverse hexagonal to lamellar phase transition. 
Figure 5.8 shows the time dependent size of mRNA–LNPs at pH 6, pH 8, following dilution 
from pH 6 to pH 8, and following dilution from pH 8 to pH 6. At pH 6 and pH 8 the mRNA–
LNPs are approximately 32 nm and 46 nm in radius, respectively, and remain at that size over 
the course of the experiment. Upon dilution from pH 8 into pH 6 the mRNA–LNPs instantly 
(within 2 min of dilution) increased in size from 32 to 36 nm and steadily increased in size to 45 
nm after 6 hrs. Following dilution from pH 6 to pH 8 there was no significant change in size. The 
irreversible nature of this process may signify that the lamellar mRNA–LNPs at pH 8 is a 
kinetically trapped phase. This is consistent with the FTIR and CD data which show that the 
lipids are more organized and the mRNA more structured at lower pH, probably indicating a 
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more thermodynamically stable complex. It is also implied that inverse hexagonal phase is more 
stable since at pH 5 and 6 there is a transition from an inverse hexagonal to lamellar phase as 
temperature increases. 
5.4 Discussion 
mRNA–LNPs have been studied by several groups previously using a combination of 
SAXS and cryo-TEM to better understand their structure9–12. LNPs of a similar composition 
have been previously examined by SAXS and determined to possess lipid inverse hexagonal 
structure at low pH in ethanol citrate buffer for both empty and siRNA encapsulating LNPs9. 
The inverse hexagonal structure was determined by three peaks in a q-position ratio of 1:√3:√4. 
A q peak at 1 nm–1 corresponded to a cylinder center to center distance of ~6 angstroms for the 
inverse hexagonal packing arrangement9. However, following dialysis into a PBS buffer only the 
q peak at 1 nm–1 remained suggesting a lamellar or multilamellar LNP structure. Here we 
showed mRNA–LNPs of the same composition also undergo a phase change upon change of 
solution pH and temperature. We did not perform SAXS experiments so our phase assignments 
are only tentative but we have a good deal of confidence since the particles used in that previous 
work and the particles used here have the same composition and the only difference is the 
particles here encapsulated EGFP mRNA (996 bases) while those particles encapsulated poly A 
(600 – 4000 bases). The carbonyl stretching observed using FTIR was also suggestive of an 
inverse hexagonal to lamellar phase transition as a function of pH, further solidifying our 
confidence in the phase assignments. 
The phase transition from an inverse hexagonal structure (below pKa) to a lamellar 
structure (above pKa) perturbed many physical characteristics of the mRNA–LNPs. The RNA 
within the particles assumed a more A form tertiary structure below the pKa. The lipids within 
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the bilayers showed an increase in kinked methylene groups above their pKa. Since kinked lipids 
pack less tightly in bilayers we hypothesize that more loosely packed lipids caused the increase in 
size of the mRNA–LNPs above the pKa. Perhaps the most striking was the fact that particles at 
lower pH were more efficient at transfection of HeLa cells. This is somewhat surprising since 
upon dilution of the particles in the HeLa cell media they are all at the same pH and thus would 
assume the same internal structural organization. This indicated that conversion between inverse 
hexagonal and lamellar mRNA–LNPs is a kinetic process which happens on a similar or longer 
time scale as cellular transfection. We confirmed this using pH-jump experiment in Figure 5.8 to 
show that following a change in pH from 8 to 6 the mRNA–LNPs take approximately 6 hrs to 
undergo a phase change from the lamellar to inverse hexagonal structure. However, solution 
conditions are significantly more crowded within liposomes than the solutions used which may 
alter the kinetics of the phase transition. Wittrup et al.24 have shown that the transfection process 
begins after ~1 hr with a t1/2 of 2 hrs. They were also able to show the time from endocytosis to 
release in the cytosol takes approximately 15 minutes. Our findings suggest that using mRNA–
LNPs already in the inverse hexagonal form may increase endosomal escape. This is consistent 
with previous work by Koltover et al.25 on cationic liposome-DNA complexes which 
demonstrated that inverse hexagonal complexes more rapidly fuse with anionic vesicles than 
lamellar complexes and thus release DNA more readily. We hypothesize that since the endocytic 
process may be more rapid than the phase transition for some fraction of the mRNA–LNPs. This 
is part of the reason cells were more efficiently transfected at pH 4. This is consistent with 
previous findings of Gilleron et al.26 that only 1 – 2% of siRNAs delivered by LNPs escape from 
the endosomes into the cytosol.  
Transfection efficiencies were equivalent using pH 4 and pH 5 buffered mRNA–LNPs and 
steadily decreased as the pH of the buffer increased. The phase transition from inverse hexagonal 
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to lamellar had many disparate characteristics such as the particle size, the amount of methylene 
kinks, and the tertiary structure of the mRNA within the particles. The methylene stretching 
frequency varied more gradually with pH suggesting more solvent-like properties of the lipids at 
higher pH. The ability of mRNA to change conformation while inside LNPs may depend on the 
solvent-like properties of the lipids. The kinetic process of a lamellar to inverse hexagonal phase 
transition seems to be able to occur even at 25 °C as supported by the size increase in the 
particles stored at pH 7 and 8 after four weeks. This further suggests the lamellar phase is 
kinetically trapped. Transfection efficiency appeared most correlated with carbonyl stretching. 
Observed carbonyl stretching frequencies increased in a sigmoidal fashion with pH. 
Approximately 40% of DLin-MC3-DMA is expected to be protonated at pH 6 and thus a 
mixture of the two phases should be expected at time zero. The carbonyl stretching frequency at 
pH 6 is 1731 cm–1 indicating a partially lamellar and partially inverse hexagonal structure. 
Future experiments could use the carbonyl stretching frequency (in concert with other FTIR 
peaks) as a rapid method for phase order determination of mRNA–LNPs. 
mRNA–LNPs are typically lyophilized for storage and reconstituted in PBS for use in 
clinical applications3,27. Developing a stable liquid formulation could significantly reduce process 
development costs. However, the poor stability of mRNA–LNPs observed here indicates this is a 
difficult task. When mRNA–LNPs had an inverse hexagonal structure they were significantly 
more stable with time. Therefore, development of a liquid formulation designed to maintain an 
inverse hexagonal structure may be critical. Since the inverse hexagonal structure appears to be 
more thermodynamically stable, it may be possible to perform two dialysis and reconcentration 
steps: first to pH 5 to form the inverse hexagonal structure and then to a second pH for the 
formulation. Even at a pH above the pKa the mRNA–LNPs should maintain the inverse 
hexagonal structure. Formulation at a pH greater than 5 could be beneficial since aggregation 
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propensity from optical density experiments was highest at pH 4 and 5. Understanding the 
determinants of aggregation propensity of mRNA–LNPs is an exciting avenue for future 
research. 
5.5 Conclusion 
To elucidate structural and colloidal properties of mRNA–LNPs across a range of solution 
conditions, we applied an array of biophysical techniques. The mRNA–LNPs have inverse 
hexagonal structure below their pKa and above the pKa have a lamellar structure. At higher 
temperatures the low pH inverse hexagonal phase transitioned to a lamellar structure, indicating 
the inverse hexagonal phase is more stable. Overall there was significantly more structure at low 
pH as indicated by the increased A form mRNA and the lipid methylene stretching vibrations. 
We summarized the phase behavior of the mRNA–LNPs with an empirical phase diagram which 
captured at least six distinct phases. We then performed short-term stability at 4 and 25 °C at five 
different pH conditions. At time zero particles formulated at the lowest pH had the highest 
transfection efficiency. mRNA–LNPs formulated at pH 4 and 5 were most stable, retaining up to 
approximately 70% of their transfection ability after 6 weeks at 4 °C. At pH 6, 7, and 8 all 
transfection efficiency was lost after 4 weeks at 4 °C. We hypothesized that the difference in 
transfection efficiency at time zero between different pH values was due to the kinetics of the 
mRNA–LNP phase transition. pH-jump kinetic experiments suggested that the lamellar phase is 
kinetically trapped since a jump from a pH above the pKa to below resulted in a lamellar to 
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5.7 Figures and Tables 
 
Figure 5.1. (A) Experimental pKa measurement by a TNS fluorescence assay. (B) size 
measurement of LNPs and mRNA–LNPs using DLS as a function of pH. (C) zeta pototential 





Figure 5.2. Circular dichroism of (A) EGFP mRNA and (B) mRNA–LNPs as a function of pH. 






Figure 5.3. DSC chromatograms for mRNA, mRNA–LNPs, and empty LNPs. (A) DSC 
thermograms of EGFP mRNA from pH 4 to 8. (B) DSC thermograms of mRNA–LNPs from pH 4 to 8. (C) 








Figure 5.5. (A) FTIR spectra for mRNA–LNPs at each pH. (B) Peak position of C-N stretching peak. 
(C) C=O stretching vibration peak maximum of mRNA–LNPs at pH 4 to 8 from 10 to 90 °C. (D) CH2 
scissor band peak maximum of mRNA–LNPs at pH 4 to 8 from 10 to 90 °C. (E) Peak intensity of the CH2 





   






Figure 5.7. Measurement of % GFP positive cells of mRNA–LNPs during storage at (A) 4 °C and 
(E) 25 °C. RNA concentrations measured using ribogreen assay at of mRNA–LNPs during storage at (B) 
4 °C and (F) 25 °C. Encapsulation efficiencies measured using ribogreen of mRNA–LNPs during storage 






Figure 5.8. Kinetic analysis of pH-dependent size of mRNA–LNPs following dilution.  
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Figure 5.S2. (A) FTIR spectra of the methylene symmetric and asymmetric stretch for mRNA–LNPs 
from pH 4 to 8. (B) Peak position of the methylene symmetric stretching band as a function of pH and 





































Formulation development of turbid solutions is becoming necessary in the 
biopharmaceutical industry.  Almost all drugs in the gene delivery field are turbid since encasing 
genetic material (RNA, DNA) for delivery requires particles of a fairly large size (at least 20 nm in 
diameter). Formulations of monoclonal antibodies are at higher and higher concentrations to 
achieve infrequent dosing which can hopefully be applied in the home. Vaccine adjuvants are 
often turbid as well, for example the most common adjuvant Alhydrogel is made up of micron 
sized particles. In this thesis we both adopted existing techniques and developed novel ones for 
characterization of turbid solutions.  
In chapter two we developed a novel technique for measurement of absorbance of turbid 
solutions. We used an integrating cavity absorbance spectrometer to collect scattered light for 
quantification. We applied this to quantify the concentration of proteins in solutions with gold 
nanoparticles, Alhydrogel, and within polymeric microparticles. The pathlength of the 
integrating cavity depends on the absorbance of the solution in a nonlinear manner. The 
relationship between absorbance on concentration was quantified using a nonlinear fit. Overall 
this technique makes it possible to measure the concentration of turbid solutions directly without 
requiring the addition of other labels or dyes. 
While we focused on measuring the concentration of protein solutions this technique could 
be expanded to measure the concentration of DNA and RNA in turbid solutions. We have done 
preliminary experiments which demonstrated this is possible for mRNA-lipid nanoparticles. 
However, the current incarnation of this instrument requires large sample volumes (~1 mL) of 
which we did not often have sufficient quantity. Miniaturizing this instrument, similar to the 
method used by nanodrop to miniaturize a classic cuvette-based absorbance spectrometer, could 
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greatly benefit the widespread adoption of this technique. Furthermore, the current light source 
does not emit sufficient light in the deep UV. This prevents measurement of the peptide bond for 
concentrations of proteins low in aromatic amino acids.  
In chapter three we examined how PS80 degradation effects protein aggregation. 
Polysorbate was degraded either by oxidation or hydrolysis and mixed with a monoclonal 
antibody. Mechanical agitation stability studies showed protein aggregation was significantly 
accelerated when mixed with hydrolyzed PS80. Aggregate particles showed a different 
morphology in the presence of hydrolyzed PS80. Lipid precipitation was identified as 
accelerating aggregation since the free fatty acids created in hydrolyzed PS80 have a relatively 
low solubility. Hydrolyzed PS80 also exhibited distinct surface properties with a lower rate of 
surface absorption and lower surface pressure at equilibrium than control or oxidized PS80.  
In the future we would like to understand how oxidation of PS80 may result in protein 
oxidation. While PS80 oxidation may not have a large impact on protein aggregation, it is the 
possible creation of radicals in solution which could oxidize proteins. Oxidation of proteins can 
result in the loss of three-dimensional structure and thus result in loss of therapeutic efficacy. 
Methods for detection of PS80 hydrolysis at low levels are also worth developing since they could 
be early indicators of formulation instability.  
In chapter four we applied a variety of characterization techniques to understand protein 
phase separation induced structural changes in monoclonal antibodies. We used three different 
monoclonal antibodies which exhibited phase separation and created phase diagrams for all of 
them. We showed that tryptophan is more buried in the protein-rich phase using fluorescence 
spectroscopy. Differences in secondary structure and the disulfide bond conformations were 
quantified using Raman spectroscopy and FTIR. For two of the proteins we used HX-MS to 
identify specific sequences responsible for protein phase separation. For one antibody oppositely 
	 188 
charged positive and negative patches were responsible protein-self association. For another 
antibody a large hydrophobic region on the variable domain exhibited protection at high protein 
concentrations. Since protein-rich and -poor phases have the same chemical potential we 
hypothesized they would aggregate at the same rate. For all three antibodies, the protein-rich 
phase aggregated at the same rate or slower than the protein-poor phase.  
In the future it would be worthwhile to compare antibodies which do not exhibit phase 
separation to those which do to see how the structure of antibodies depends on concentration 
independent of solution phase behavior. Repulsive interactions between proteins could also result 
in structural changes at high solution volume fractions of proteins. To develop a better 
understanding of the concentration effects of antibody solution structure a large panel of different 
antibodies would be required. Even the behavior we observed had some amount of specificity 
among the individual proteins examined such as the disulfide ratios seen by Raman spectroscopy, 
aggregation rates, and the sites of contact based on HDX studies. Another future experiment 
would be to use another commonly studied system such as lens crystallines to see if structural 
changes occur following phase separation in other types of proteins. 
In chapter five we characterized the pH-dependent properties and stability of mRNA–
cationic lipid nanoparticles. mRNA-LNPs showed a shift from inverse hexagonal structure below 
the pKa of the cationic lipid to lamellar above. To characterize the lipid phase structure, we used 
FTIR and DSC. To characterize the mRNA within the particle we used circular dichroism. In 
the inverse hexagonal phase the mRNA showed an increase in A form geometry. The particles 
were approximately 10 nm greater in radius below the pKa of the cationic lipid. We measured 
the stability of the mRNA–LNPs at 4 and 25 °C and at low pH the particles exhibited much 
greater stability. We attributed this to the increased organizational structure and thermodynamic 
stability of the inverse hexagonal phase. We also showed that following a pH-jump from 8 to 6, 
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the particles underwent a lamellar to inverse hexagonal phase change over 6 hours but the 
opposite pH-jump did not result in a phase change. This suggested that the lamellar phase is 
kinetically trapped and less thermodynamically stable than the inverse hexagonal phase. 
mRNA–LNPs are a relatively new therapeutic modality and we still have many 
unanswered questions following our work. Small angle scattering experiments would be useful to 
confirm our phase behavior assignments. Determination of how mRNA size and/or sequence 
effect the phase behavior of mRNA–LNPs is also an unexplored topic. Most pressing for 
formulation development is a more sophisticated understanding of mRNA–LNP degradation. 
Mass spectrometry methods must be developed both for the lipids and mRNA and specific 
degradation products identified. Once this has been completed, the specific impacts of various 
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